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ABSTRACT
Polyamines (putrescine, spermidine and spermine) are ubiquitous low molecular weight amines
that are positively charged under physiological conditions. Homeostatic control of intracellular
polyamine levels is achieved by regulating the synthesis, catabolism and transport of these
molecules. Spermidine/spermine N1-acetyltransferase  (SSAT)  is  the  key  enzyme  in  the
catabolism of polyamines. The overexpression or loss of this enzyme leads to the corresponding
activation or deficiency of polyamine catabolism. Polyamines are involved in many cellular
processes such as cell growth, signal transduction, stabilization of negative charged
macromolecules, modulation of potassium and calcium channels and stimulation of transcription
and translation. Since transgenic mice overexpressing SSAT (SSAT mice) surprisingly exhibited
reduced subcutaneous white adipose tissue (WAT) mass, the role of polyamine catabolism in the
regulation of glucose, energy and lipid metabolism was investigated using transgenic mice
overexpressing or deficient for SSAT.
The characterization of SSAT mice revealed that these mice exhibited severely reduced
whole body WAT mass, elevated energy expenditure, high insulin sensitivity, a low tissue
triglyceride content, increased number of mitochondria and overexpression of the oxidative
phosphorylation genes coordinated by increased levels of peroxisome proliferator activated
receptor  co-activator 1 (PGC-1) in WAT. The induction of PGC-1 was attributable to
activated polyamine catabolism-mediated depletion in the cellular ATP pool which activated the
cellular energy sensor, 5’-AMP-activated protein kinase (AMPK) and PGC-1. These results
suggest that the enhancement of cellular ATP consumption is an efficient way to reduce body
WAT mass and improve glucose metabolism.
Furthermore, activated polyamine catabolism caused a significant reduction in plasma
total cholesterol levels in SSAT mice by increasing the elimination of cholesterol from the body
via bile acid synthesis. The hepatic expression of cholesterol 7-hydroxylase (CYP7A1), the
rate-limiting gene in bile acid synthesis, was induced by PGC-1, the protein stability and
activity of which was increased most likely due to the reduction in the protein levels of Akt
evoked by activated polyamine catabolism. Therefore, activation polyamine catabolism is a novel
way of inducing bile acid synthesis and lowering circulating total cholesterol levels.
The deficiency in polyamine catabolism resulted in insulin resistance in aged SSAT
knockout (KO) mice. Thus, the maintenance of normal glucose homeostasis seems to require
functional polyamine catabolism. However, the deficiency of polyamine catabolism did not
evoke any major changes in body WAT mass or lipid metabolism in SSAT-KO mice.
Our results demonstrate that polyamine catabolism is involved in the regulation of energy
balance, and glucose and cholesterol metabolism in mice.
National Library of Medicine Classification: QU 61
Medical Subject Headings: Polyamines/metabolism; Metabolism; Acetyltransferases; Animals,
Genetically Modified; Mice, Transgenic; Homeostasis; Glucose/metabolism; Energy
Metabolism; Lipid Metabolism; Cholesterol/metabolism; Bile Acids and Salts/metabolism;
Adipose Tissue, White/growth & development; Adipose Tissue, White/cytology; Liver; Gene
Expression; Trans-Activators/genetics; Trans-Activators/metabolism; AMP-Activated Protein
Kinases; Cholesterol 7-alpha-Hydroxylase.
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1 INTRODUCTION
Energy is required for all cellular processes (Alberts et al., 1994). Energy homeostasis occurs
when energy intake is matched to energy expenditure through complex peripheral and
central regulatory pathways. Energy obtained from the chemical bonds present in nutrients is
released  during  cellular  respiration  and  this  energy  is  used  to  form  the  cellular  energy
currency, ATP, through oxidative phosphorylation (OXPHOS) in mitochondria.
Glucose is a vital source of energy in the cell (Murray et al., 1993; Aronoff et al.,
2004). In particular, the brain is entirely dependent upon glucose as a fuel. The circulating
glucose level is under the homeostatic control in order to maintain a near-constant glucose
level to protect the brain from fuel deprivation. Several hormones, particularly insulin and
glucagon, act to control glucose levels. An increase in the glucose concentration stimulates
the pancreas to release insulin, and insulin in turn promotes glucose uptake in peripheral
tissues. A low glucose level stimulates the pancreas to release glucagon which promotes the
hepatic conversion of organic molecules such as lactate, pyruvate, glycerol and amino acids
to glucose through gluconeogenesis. In addition, glucagon stimulates glycogen breakdown to
glucose to normalize the blood glucose levels.
Cholesterol is an important membrane component serving as a precursor for the
synthesis of bile acids, steroid hormones and D vitamin (Murray et al., 1993). Bile acids are
known to be important for the solubilization of other lipids but they also act as regulatory
molecules (Hylemon et al., 2009). Bile acids enhance energy expenditure via cyclic AMP
(cAMP)-dependent thyroid hormone activation (Watanabe et al., 2006) and control glucose
homeostasis by inducing insulin signaling in the liver (Dent et al., 2005). The intracellular
cholesterol content is regulated via coordinated control of cholesterol synthesis, secretion
and uptake (Dietschy et al., 1993). The balance of bile acid synthesis, biliary excretion and
reabsorption from the small intestine plays a pivotal role in the regulation of cellular
cholesterol homeostasis.
Peroxisome proliferator activated receptor  co-activator  1  (PGC-1)  (PGC-1)  is  a
key factor regulating energy and glucose homeostasis by stimulating mitochondrial
biogenesis, fatty acid oxidation, OXPHOS, uncoupling, thermogenesis, gluconeogenesis and
glucose transport (Puigserver and Spiegelman 2003). Overexpression of PGC-1 in white
adipose tissue (WAT) reduces WAT mass, increases metabolic rate, uncoupling and insulin
sensitivity in mice (Cederberg et al., 2001; Tsukiyama-Kohara et al., 2001). In addition to
being the key regulator of energy metabolism, PGC-1 also participates in the control of
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cholesterol homeostasis because it stimulates the rate-limiting gene in hepatic bile acid
synthesis, cholesterol 7-hydroxylase (CYP7A1) (Shin et al., 2003).
The naturally occurring polyamines, putrescine, spermidine and spermine, are small
cationic molecules that are found in all eukaryotic cells (Jänne et al., 2005). One well-known
function of polyamines is their ability to promote cell growth and neoplastic transformation.
The polyamine content in the cell is regulated through the complex control of synthesis,
catabolism, uptake and excretion. The rate-limiting enzyme in polyamine catabolism is
spermidine/spermine N1-acetyltransferase (SSAT). Overexpression of this enzyme activates
polyamine catabolism leading to the accumulation of putrescine and a reduction in the
spermidine and/or spermine pools. Transgenic mice having ubiquitous overexpression of
SSAT (SSAT mice) were originally generated for cancer research. Since SSAT mice had
severely reduced subcutaneous WAT mass (Pietilä et al., 1997), we investigated the
involvement of polyamine catabolism in the regulation of glucose, energy, and cholesterol
metabolism and especially in the control of PGC-1 expression in WAT and liver using
mice either overexpressing or deficient for SSAT.
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2 REVIEW OF LITERATURE
2.1 Polyamine metabolism
2.1.1 Overview of polyamines
The polyamines, putrescine, spermidine and spermine, are small aliphatic molecules that
exists in all eukaryotic cells (Cohen 1998). They have two or more primary amino groups and
are positively charged at physiological pH. Due to their cationic nature, polyamines can
interact very tightly via hydrogen bonding, ionic and covalent linkages, and hydrophobic
interactions with negatively charged molecules such as DNA, RNA, proteins and
phospholipids  and  this  way  they  can  change  their  structure  and function. Polyamine
metabolism can be more preferably viewed as a cycle rather than as two distinct linear
pathways consisting of synthesis and catabolism (Fig. 1).
Putrescine
SpermidineSpermidine
Spermine
Ornithine
SSAT/PAO
SSAT/PAO
SMO
Spd
synthase
Spm
synthase
AdoMet
Met
+
ATP
AdoMet
Met
+
ATP
dcAdoMet
dcAdoMet
Acetyl-CoA
Acetyl-CoA AdoMetDC
AdoMetDC
1.
2.
3.
4.
ODC
Figure 1. Polyamine cycle. Spd, spermidine; Spm, spermine; Met, methionine and AdoMet,
S-adenosylmethionine. Modified from (Jänne et al., 2005).
2.1.2 Synthesis
2.1.2.1 Overview
The enzymes involved in the biosynthesis of polyamines are ornithine decarboxylase (ODC),
S-adenosylmethionine decarboxylase (AdoMetDC), spermidine synthase (SPDSy) and
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spermine synthase (SPMSy) (Fig. 1) (Cohen 1998). The first rate-limiting step in the
synthesis of polyamines is the formation of putrescine by decarboxylation of L-ornithine,
which is catalyzed by ODC (EC 4.1.1.17). This is followed by the conversion of S-
adenosylmethionine to decarboxylated S-adenosylmethionine (dcAdoMet) by AdoMetDC
(EC 4.1.1.50). The addition of dcAdoMet to putrescine leads to the synthesis of spermidine
via the action of SPDSy (EC 2.5.1.16). The addition of dcAdoMet to spermidine then leads to
synthesis of spermine catalyzed by SPMSy (EC 2.5.1.22). In mammals, ornithine is an
exclusive precursor for de novo synthesis of polyamines. It can be derived from the
circulation or it can be synthesized within the cell from arginine by the enzyme arginase.
2.1.2.2 Ornithine decarboxylase
Eukaryotic ODC is a pyridoxal phosphate-dependent enzyme which acts as a homodimer
(Coleman et al., 1994). ODC has a very low half-life (~10-30 min) (Davis et al., 1992). The
stability of ODC is regulated by a protein termed antizyme (AZ) which binds to ODC
monomer and directs ODC to degradation by the 26S proteosome (Elias et al., 1995). A
decline in polyamine concentrations triggers a decrease in the transcription and translation of
AZ while high levels of polyamines increase AZ content by increasing synthesis and reducing
degradation (Nilsson et al., 1997). The effect of AZ on ODC can be blocked by antizyme
inhibitor which binds AZ more tightly than ODC and thereby releases ODC from the ODC-
AZ complex (Murakami et al., 1996; Nilsson et al., 2000). Another level of the control of the
ODC protein amount is translational regulation by polyamines through cap-dependent and –
independent mechanisms (Shantz and Pegg 1999; Pyronnet et al., 2000). Third level
regulation of ODC occurs in transcription which is affected by many factors e.g. hormones,
growth factors and oncogene c-myc (Pegg 2006). A specific inhibitor of ODC,
difluoromethylornithine (DFMO) has been evaluated as a cancer chemopreventive agent due
to its capability to deplete intracellular polyamine content (Gerner and Meyskens 2004).
2.1.2.3 S-adenosylmethionine decarboxylase
The second rate-limiting enzyme in the biosynthesis of polyamines is AdoMetDc which has a
moderately rapid turnover (a half-life about 1-3 h) (Stjernborg and Persson 1993).
AdoMetDC  is  a  pyruvoyl  enzyme  which  is  synthesized  as  a  proenzyme  that  undergoes  an
intramolecular cleavage reaction forming - and -subunits (Pegg et al., 1998). In mammals,
AdoMetDC exists as a tetramer consisting of two pairs of - and -subunits. Growth factors
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and hormones like insulin increase the transcription of AdoMetDC (Soininen et al., 1996).
Putrescine increases the activity of AdoMetDC and accelerates the cleavage of proenzyme
(Pegg et al., 1988; Stanley et al., 1994). High levels of spermidine and spermine suppress the
transcription and mRNA translation of AdoMetDC whereas depletion of these higher
polyamines increases the mRNA and protein synthesis (Shirahata and Pegg 1986; White et
al., 1990; Shantz et al., 1992).
2.1.2.4 Spermidine synthase and spermine synthase
SPDSy and SPMSy share similar properties. Both consist of two identical subunits, they are
constitutively expressed and the proteins are substantially more stable than ODC and
AdoMetDC (Pegg 1986; Kajander et al., 1989; Seiler 1990). These enzymes have been less
extensively studied since they do not play a rate-limiting role in polyamine biosynthesis.
2.1.3 Catabolism
2.1.3.1 Overview
Intracellular polyamine concentrations are also controlled by catabolism, allowing the
conversion of spermine and spermidine back to putrescine (Cohen 1998). The polyamine
catabolism involves acetylation of spermidine and spermine by the rate-limiting enzyme
SSAT (Fig. 1) (EC 2.3.1.57). Acetyl-CoA is the acetyl group donor for this reaction in which
SSAT transfers the acetyl group from acetyl-CoA to the N1-positions of spermidine and
spermine. Thereafter, polyamine oxidase (PAO) (EC 1.5.3.11) converts acetylated
polyamines into spermidine and putrescine, respectively (Fig. 1). In addition, spermine can be
converted directly to spermidine without acetylation by spermine oxidase (SMO) (Fig. 1.)
(EC 1.5.3.3) (Vujcic et al., 2003).
2.1.3.2 Spermidine/spermine N1-acetyltransferase
Human SSAT gene is located on chromosome Xp22.1 (Xiao et al., 1992) and it encodes a 20
kDa protein consisting of 171 amino acids (Casero et al., 1991). The SSAT gene contains six
exons which encode mRNAs of about 1.3 and 1.5 kb (including polyA) (Fogel-Petrovic et al.,
1993). An alternative splice variant including an additional 110 bp exon between exons 3 and
4 has also been identified (Hyvönen et al., 2006). The promoter region of SSAT lacks a
TATA box but contains putative recognition sequence(s) for polyamines and transcription
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factors such as Sp1, AP1, nuclear factor B, CCAT/enhancer binding protein , cAMP
response element binding protein (CREB) and peroxisome proliferator activated receptor
(PPAR)  (PPAR) (Wang et al., 1998; Tomitori et al., 2002; Ignatenko et al., 2004; Pegg
2008).
SSAT is considered to be predominantly a cytosolic enzyme, but recent studies have
revealed that SSAT also localizes into nucleus and mitochondria (Holst et al., 2008; Uimari et
al., 2009). SSAT acts as a homodimer (Bewley et al., 2006) and has a rapid turnover rate
having a half-life less than 30 min (Matsui and Pegg 1981; Persson and Pegg 1984). Under
basal conditions, the SSAT activity is very low but SSAT shows high inducibility in response
to several factors including polyamines and polyamine analogues (Pegg 2008), stress, fasting,
hormones, growth factors, toxic agents, nonsteroidal anti-inflammatory drugs (Babbar et al.,
2006) and resveratrol (Ulrich et al., 2006). The induction of SSAT activity by polyamines
and polyamine analogues occurs through several mechanisms. Gene transcription is increased
by polyamines via nuclear factor erythroid 2-related factor 2 which binds to the polyamine
response element in the promoter of SSAT gene (Wang et al., 1998). Polyamines and
polyamine analogues increase the stability of SSAT mRNA (Fogel-Petrovic et al., 1993;
Fogel-Petrovic  et  al.,  1996;  Hyvönen et  al.,  2006),  mRNA translational  efficiency  (Parry  et
al., 1995) and stabilize SSAT protein by preventing its ubiquitination and targeting to
proteosomal degradation (Coleman and Pegg 2001). The other inducers of SSAT differs from
polyamines and polyamine analogues in that they may increase SSAT activity by elevating
the cellular content of polyamines either by increasing polyamine synthesis or by releasing
polyamines from bound sites but also by increasing the transcription through the multiple
binding sites for the transcription factors (Pegg 2008). N1,N11-diethylnorspermine
(DENSPM), an N-alkylated polyamine analog, is the most potent and widely used SSAT
activator which has been demonstrated to cause growth inhibition e.g. by depleting polyamine
pools, inhibiting mitochondrial protein synthesis and production of reactive oxygen species
(Snyder et al., 1994; Casero et al., 2005).
The activation of polyamine catabolism by overexpression of SSAT in vivo causes a
massive putrescine accumulation, the appearance of N1-acetylspermidine and a reduction in
spermidine and/or spermine pools (Pietilä et al., 1997). The initial fall in the spermidine and
spermine pools compensatorily increases polyamine biosynthesis, leading to a continuous
supply of polyamines for acetylation by SSAT. This accelerates the turnover rate of
polyamine cycle and the overall flux of polyamines (Jänne et al., 2006). As a consequence of
the enhanced polyamine flux, the consumption of the SSAT co-factor acetyl-CoA, a central
21
metabolic intermediate, increases. Indeed, markedly reduced acetyl-CoA pools have been
detected in prostate and WAT of SSAT mice (Kee et al., 2004; Jell et al., 2007).
2.1.3.3 Polyamine oxidase and spermine oxidase
PAO is a flavin adenine dinucleotide-dependent amino oxidase which uses mainly acetylated
polyamines as its preferred substrates (Seiler 1987). PAO is a constitutively expressed protein
having a long half-life (seven days) (Seiler et al., 1980) but N-alkylated polyamine analogues
have been shown to induce the enzyme slightly (Vujcic et al., 2003). A recently discovered
enzyme, SMO, is a flavoenzyme which can use only spermine as a substrate (Vujcic et al.,
2003). Its expression is induced by polyamine analogues mainly at the mRNA level (Wang et
al., 2001). Both PAO and SMO produce cytotoxic H2O2 as a by-product (Seiler 1987; Vujcic
et  al.,  2002).  It  has  been  noted  that  the  release  of  H2O2 is  mainly  derived  from  SMO,  not
PAO, in polyamine analogue –treated breast cancer cells (Pledgie et al., 2005). Other
products of PAO and SMO are reactive aldehydes, acetamidopropanal and aminopropanal,
respectively (Seiler 1987; Vujcic et al., 2002).
2.1.4 Transport
Polyamine transport (uptake and export) is also one of the main ways to control the
intracellular content of polyamines. However, the transport mechanisms in mammalian cells
are not well characterized. In general, the uptake of polyamines is stimulated when the
intracellular polyamine content decreases e.g. due to the inhibition of ODC, whereas the
accumulation of polyamines stimulates export of polyamines out of cells (Seiler et al., 1996).
Extracellular source of polyamines is diet and polyamines can be also released from intestinal
microbes and other cells. The uptake is mediated through an energy-requiring transport
system but transporter gene(s) have not been cloned yet in mammals. However, a protein that
downregulates polyamine uptake has been identified. AZ, in addition to inhibiting of ODC,
reduces polyamine uptake in order to prevent the accumulation of polyamines to toxic levels
(Sakata et al., 2000). The function of polyamine exporter system is not fully understood. It
appears to be carrier-mediated and presumably not facilitated by the transporter involved in
the uptake (Seiler et al., 1996). However, AZ has been also shown to stimulate polyamine
excretion (Sakata et al., 2000). The main polyamines exported from the cell are acetylated
polyamines and putrescine whereas the predominant intracellular polyamine pool consists of
spermidine and spermine (Wallace and Mackarel 1998). Thus, polyamine export seems to be
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a selective and regulated process. Since polyamine catabolism produces acetylated
polyamines, it does appear that polyamine catabolism and export are regulated by the same
factors.
2.1.5 Functions of polyamines and polyamine metabolism
The  most  apparent  function  of  polyamines  is  their  requirement  for  cell  growth  (Tabor  and
Tabor 1984; Jänne et al., 2005). Elevated activity of ODC and the subsequent increase in
polyamine concentrations stimulate cell proliferation (Auvinen et al., 1992). In addition,
polyamines seem to regulate expression of p53, the key factor controlling the cell cycle, (Li
et al., 1999) and polyamines are required for cell cycle progression (Oredsson 2003).
Polyamines have also been shown to play an important role in the regulation of
differentiation though this effect seems to be cell-type specific. Differentiation is inhibited by
polyamines in many tumor cells (Teti et al., 2002) but in other situations polyamines are
essential e.g. during adipogenesis in 3T3-L1 cells (Bethell and Pegg 1981; Vuohelainen et al.,
2009). A very recent study revealed that spermidine is needed to support expression of the
key regulators of adipocyte differentiation, PPAR and CCAAT/enhancer binding protein 
(CEBP/) (Vuohelainen et al., 2009). In addition to cell proliferation and differentiation,
polyamines modulate many types of ion channels such as inward-rectifier potassium channels
(Oliver et al., 2000; Phillips and Nichols 2003), voltage dependent Ca2+ channels,  and  N-
methyl-D-aspartic acid receptors (Williams 1997) Furthermore, polyamines stimulate
transcription and translation (Coffino 2000), stabilize DNA (Tabor 1962) and act as signaling
molecules (Bachrach et al., 2001).
The role of polyamines in glucose and lipid metabolism has been largely unexplored.
Spermidine and spermine can mimic insulin in isolated rat adipocytes (Lockwood and East
1974) and increase the stability of insulin mRNA (Welsh 1990) and stimulate proinsulin
biosynthesis (Sjöholm 1993). Furthermore, polyamines, especially spermidine and spermine,
possibly increase the activities of 1,2-diacylglycerol acyltransferase (Jamdar and Osborne
1983) and lipoprotein lipase (LPL) (Giudicelli et al., 1976) but inhibit lipolysis induced by
epinephrine (Lockwood and East 1974). In contrast, a recent study demonstrated that
spermidine is essential for the expression of hormone sensitive lipase (HSL), the rate-limiting
enzyme for lipolysis, and fatty acid synthase (Vuohelainen et al., 2009). The role of
putrescine in glucose metabolism has remained unclear due to controversial results regarding
its effect on glucose transport (Lockwood et al., 1971; Shelepov et al., 1990). Putrescine
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together with spermine has been shown be important for the maintenance of mitochondrial
respiratory chain activity in tumor-bearing mice (Ushmorov et al., 1999).
2.1.5.1 Physiological effects of SSAT overexpression
In humans, SSAT overexpression has been claimed to be involved in some disease states.
Keratosis follicularis spinulosa decalvans is a rare X-linked syndrome, which is caused by the
duplication of X-chromosomal region containing the SSAT gene (Fig. 2) (Gimelli et al.,
2002). This disease causes follicular hyperkeratosis, alopecia and alterations that affect
vision. Isolated fibroblasts from these patients display increased SSAT activity and putrescine
accumulation.
SSAT
Hair loss
KFSD
Liver regeneration
Pancreatitis
Fat mass
Carcinogenesis
Depletion of higher polyamines
Elevated putrescine content
Reactive oxygen species
Reduced acetyl-CoA
Figure 2. Effects of SSAT overexpression. KFSD, keratosis follicularis spinulosa decalvans.
(Modified from (Pegg 2008). The shading of the boxes presents the most likely cause for the
physiological change.
The characterization of transgenic mice ubiquitously overexpressing SSAT has revealed
a variety of effects of increased SSAT activity on normal physiology. SSAT mice have a
permanent  hair  loss  at  the  age  of  3  to  4  weeks,  reduced  subcutaneous  fat  mass  and  female
infertility due to the lack of a corpus luteum (Fig .2) (Pietilä et al., 1997). Furthermore,
behaviour and neurological changes like hypoactivity and spatial learning impairment have
been observed (Kaasinen et al., 2004). Most of these changes were proposed to be related to
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putrescine accumulation. Indeed, elevated putrescine accumulation has been shown to disturb
keratinocyte differentiation in vitro and a reduction in the putrescine levels by inhibition of
putrescine biosynthesis was sufficient to stimulate hair regrowth in SSAT mice (Pietilä et al.,
2005). Transgenic rats overexpressing SSAT under the control of the metallothionein
promoter have markedly elevated SSAT activity and thus exhibit a subsequent depletion of
spermidine and spermine pools in the pancreas and liver and these animals have been noted
to experience acute pancreatitis and a blockage of liver regeneration (Fig. 2) (Alhonen et al.,
2000; Alhonen et al., 2002). Since the treatment with stable spermidine analogues was able to
protect them from the onset of pancreatitis and to restore liver regeneration, it was concluded
that spermidine seemed to be the critical polyamine needed for the maintenance of normal
tissue integrity and growth in pancreas and liver, respectively (Räsänen et al., 2002; Hyvönen
et al., 2007).
It has been hypothesized that increased SSAT activity and a subsequent reduction in
spermidine and spermine pools would impair tumorigenesis. However, there is evidence for
and against this hypothesis (Fig. 2). For example, SSAT mice have decreased tumor
incidence in the skin when challenged in a two-stage tumorigenesis test (Pietilä et al., 2001).
Opposite results were obtained with a mouse line in which SSAT cDNA was driven by
keratin 6 promoter (Coleman et al., 2002). In addition, SSAT overexpression has been
reported to enhance tumorigenesis in mice susceptible to intestinal cancer, APCMIN/+ mice
(Debruyne et al., 2001; Tucker et al., 2005). It has been proposed that the increased number
of tumors in mice overexpressing SSAT maybe be attributable to a compensatory increase in
the biosynthesis of polyamines. Another possibility is that the generation of reactive oxygen
species from by-products of polyamine catabolism, H2O2 and reactive aldehydes, contribute
to tumor formation.
Recent studies have shown that altered SSAT expression can change WAT metabolism
in mice (Jell et al., 2007). SSAT overexpression leads to severely reduced whole body WAT
mass with a reduction in acetyl-CoA and malonyl-CoA in WAT (Fig. 2). In SSAT knockout
(SSAT-KO) mice, an opposite relationship between the metabolic intermediates and WAT
mass was observed. Malonyl-CoA is formed from acetyl-CoA in a reaction catalyzed by
acetyl-CoA carboxylase (ACC). Malonyl-CoA is considered to be a key regulator of energy
metabolism because it is an intermediate used for fatty acids synthesis (Wakil et al., 1983)
and it inhibits the rate-limiting enzyme in fatty acid oxidation, carnitine palmitoyltransferase
I (CPT-I) (McGarry and Brown 1997). Jell and coworkers suggested that the accelerated
polyamine flux would result in a diversion of acetyl-CoA to polyamine acetylation instead of
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the formation of malonyl-CoA (Jell et al., 2007). Consequently, the low malonyl-CoA levels
then activate fatty acid oxidation and inhibit fatty acid synthesis as observed in ACC2 knock-
out mice (Oh et al., 2005). Conversely, a SSAT deficiency increases the availability of acetyl-
CoA for the formation of malonyl-CoA which causes increased fatty acid synthesis and
reduced fatty acid oxidation with a concomitant increase in WAT accumulation. Therefore,
polyamine catabolism does seem to be an important regulator of lipid and energy metabolism.
2.2 Regulation of glucose homeostasis
2.2.1 Overview
Lower blood glucose
Higher blood glucose
 - cells release
glucagon
glycogen breakdown
and gluconeogenesis
- cells release
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glycogen synthesis
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Food
stimulates
Figure 3. The maintenance of glucose homeostasis.
The maintenance of blood glucose concentration at a near-constant level is crucial to ensure a
continuous supply of glucose to the brain (Murray et al., 1993). Glucose homeostasis is
controlled very similarly in humans and mice through insulin secretion by the pancreas,
hepatic glucose output, and glucose uptake by liver and peripheral tissues (skeletal muscle
and WAT) (Aronoff et al., 2004). The main hormones regulating glucose homeostasis are
insulin and glucagon, and the balance between these two hormones is the key factor in the
control of glucose homeostasis. Other important hormones are e.g. epinephrine and
glucocorticoids.
Glucose can enter the circulation from three sources: intestinal absorption after the
digestion of food, glycogen breakdown and gluconeogenesis (Aronoff et al., 2004). When the
blood glucose concentration raises, pancreatic -cells release insulin into the circulation (Fig.
3.). The result is a lowering of blood glucose concentration. When blood glucose is low,
26
pancreatic -cells release glucagon into the circulation thereby elevating the blood-glucose
concentration to the desired level (Fig. 3).
2.2.2 Insulin
Insulin is the key anabolic hormone which reduces glucose levels by stimulating glucose
uptake in peripheral tissues, increasing glycogen synthesis and inhibiting hepatic glucose
production (Murray et al., 1993; Aronoff et al., 2004). Insulin promotes the storage of lipids
by increasing triglyceride (TG) synthesis, inhibiting lipolysis, enhancing hydrolysis of TGs
from either hepatic very-low-density lipoproteins (VLDLs) or dietary chylomicrons and
inhiting the conversion of diet-originated free fatty acids (FFAs) to TG-rich VLDL particles.
In addition, insulin promotes the storage of proteins by increasing the synthesis and
enhancing the cellular uptake of amino acids in liver and skeletal muscle.
GLUT4
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Insulin
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translocation
PI3K
Akt
AS160
Cbl/CAP
SHC
Grp2/SOS
MAPK
Gene
expression
Cell growth
and
differentiation
Glycogen synthesis,
lipolysis and
protein synthesis
Ras
Figure 4. Simplified overview of insulin signalling pathways. Grp2, growth receptor binding
protein 2; SOS, Son of sevenless; IRS, insulin receptor substrate proteins; CAP, Cbl-
associated protein and Cbl, c-Cbl proto-oncogene.
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The effects of insulin are mediated through the integrated network of insulin signalling
molecules (Fig. 4). The initial step in the signal transduction cascade is the binding of insulin
to its receptor which undergoes autophosphorylation of tyrosine residues (Taniguchi et al.,
2006). Increase in insulin receptor tyrosine kinase activity results in the phosphorylation of
insulin receptor substrate proteins which mediate the signal via either the
phosphatidylinositol 3 –kinase (PI3K)–Akt–Akt substrate of 160 kDa (AS160) pathway or
down the Ras-mitogen activated protein kinase (MAPK) pathway. The PI3K–Akt-AS160
pathway regulates the metabolic actions of insulin such as glucose transporter (GLUT) 4
(GLUT4) translocation and synthesis of glycogen, lipids and proteins. The Ras–MAPK
pathway regulates gene expression and stimulates cell growth and differentiation
cooperatively with PI3K-Akt pathway. In addition, the insulin receptor tyrosine kinase
phosphorylates c-Cbl proto-oncogene which forms a complex with Cbl-associated protein,
resulting in the activation of GTPase TC10 and an increase in GLUT4 translocation.
However, the importance of c-Cbl proto-oncogene/Cbl-associated protein pathway in insulin
signal transduction is not clear.
2.2.3 Glucagon
Glucagon is the key catabolic hormone consisting of 29 amino acids (Aronoff et al., 2004). It
is secreted from pancreatic -cells, and its secretion is stimulated by low and inhibited by
high concentrations of glucose. The metabolic actions of glucagon are the opposite to those
of insulin. Glucagon stimulates hepatic endogenous production of glucose and ketogenesis
and inhibits hepatic glycogen synthesis and glycolysis (Aronoff et al., 2004; Agius 2007).
2.2.4 Glucose uptake
After  an  oral  glucose  load,  approximately  one-third  of  the  total  glucose  amount  is  equally
taken up by peripheral, splanchnic (liver and intestine) and non-insulin-dependent (brain and
kidney)  tissues  (DeFronzo  2004;  Meyer  et  al.,  2002).  Skeletal  muscle  is  the  major  site  for
insulin-stimulated glucose disposal whereas only 5-10% is accomplished by WAT (DeFronzo
2004). Glucose is a hydrophilic molecule and therefore specific transport proteins are
required to allow it to enter cells (Bouche et al., 2004). In mammals, energy-independent
transport of glucose is mainly accomplished by 13 different isoforms of facilitative glucose
transporters (GLUT1-13) (Uldry and Thorens 2004). GLUT1 is a widely expressed isoform
which facilitates glucose transport in many cells under basal conditions. GLUT2 is present in
pancreatic -cells and in tissues exposed high glucose flux like intestine and liver. GLUT4
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mediates insulin-stimulated glucose uptake in skeletal and cardiac muscle, WAT and brown
adipose tissue (BAT) (Uldry and Thorens 2004). GLUT4 is found in the intracellular storage
vesicles and insulin increases the rate of GLUT4 translocation from its storage  site  to  the
plasma membrane through the mechanisms shown in Figure 4. Exercise also stimulates the
movement of GLUT4 to the cell surface through insulin-independent mechanisms including
the action of 5’-AMP-activated protein kinase (AMPK), calcium/calmodulin-dependent
protein  kinase  and  protein  kinase  C (PKC)  (Rose  and  Richter  2005).  After  transport  to  the
cell, glucose is phosphorylated to glucose-6-phosphate by different isoforms of hexokinase
(HK) (HKI-III, glucokinase) (Wilson 1995). HKII is the main isoform in insulin-sensitive
tissues whereas glucokinase is expressed in the liver and pancreas.
2.2.5 Glycolysis and glucose oxidation
Glycolysis  is  the  main  pathway  for  glucose  utilization  (Murray  et  al.,  1993;  Bouche  et  al.,
2004). It occurs in the cytosol of all mammalian cells and it represents the formation of
pyruvate from glucose. The first phase, conversion of glucose to fructose 1,6-bisphosphate, is
the energy requiring phase and the second phase, degradation of fructose 1,6-bisphosphate to
pyruvate, is considered as an energy-yielding phase. Under anaerobic conditions (e.g. in
exercising muscle), pyruvate is metabolized to lactate in a reaction catalyzed by lactate
dehydrogenase. In the presence of oxygen, pyruvate goes down two mitochondrial steps,
citric acid cycle and respiratory chain, to produce ATP (glucose oxidation). Three irreversible
reactions catalyzed by hexokinase (or glucokinase), phosphofructokinase and pyruvate kinase
are the major sites for the regulation of glycolysis. These enzymes are under allosteric control
and  their  rate  of  transcription  is  regulated  by  insulin  and  glucagon.  The  pyruvate
dehydrogenase (PDH) complex determines the conversion of pyruvate to acetyl-CoA in
mitochondria and is the major indicator of the rate of glucose oxidation. The regulation of
PDH activity is complex, involving allosteric, post-translational and transcriptional control
mechanisms (Patel and Korotchkina 2006).
2.2.6 Endogenous production of glucose
Gluconeogenesis means the formation of glucose from noncarbohydrate sources, such as the
breakdown of muscle proteins (alanine), anaerobic glycolysis (lactate) and the glycerol
portion of fats (Murray et al., 1993; Bouche et al., 2004). The liver is the main tissue
responsible for gluconeogenesis but the kidneys can also participate to some exent in times of
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extreme starvation. Glucose-6-phosphatase (G6Pase), the enzyme necessary for the release of
glucose into the circulation, catalyzes the rate-limiting enzyme step but phosphoenolpyruvate
carboxykinase (PEPCK) plays also an important role in this process. Transcription of G6Pase
and PEPCK is stimulated by glucagon, epinephrine and glucocorticoids whereas it is
suppressed by insulin (Barthel and Schmoll 2003). Glucose storage occurs in skeletal muscle
and in liver where glucose is converted to glycogen through glycogenesis (Murray et al.,
1993; Bouche et al., 2004). Insulin stimulates the rate-limiting enzyme in glycogenesis,
glycogen synthase, by promoting its dephosphorylation while glucagon and epinephrine
induce glycogen synthase phosphorylation and inhibit its activity. Complete breakdown of
glycogen to glucose is accomplished through glycogenolysis by the concomitant action of
glycogen phosphorylase and glycogen debranching enzyme. Glucagon and epinephrine
promote glycogenolysis by increasing phosphorylation and activation of glycogen
phosphorylase whereas insulin has an opposite effect on the phosphorylation status of
glycogen phosphorylase, leading to inactivation of this enzyme (Jiang and Zhang 2003;
Bouche et al., 2004). The liver can release the newly formed glucose into the circulation for
uptake by other cells (Murray et al., 1993; Bouche et al., 2004). In contrast, skeletal muscle
uses glycogen as a source of energy only within muscle tissue itself due to the lack of G6Pase
enzyme. Both gluconeogenesis and glycogenolysis represent sources of glucose during
fasting and exercise.
2.2.7 Insulin secretion
Insulin is a peptide hormone consisting of 51 amino acids, and it is secreted from pancreatic
-cells  when  the  glucose  concentration  rises  above  a  stimulatory  level  (~5  mM)  in  the
circulation (Barg 2003). Glucose is transported into the cell via GLUT2 where it is
phosphorylated to glucose 6-phosphate by glucokinase. The increased availability of glucose-
6-phosphate increases the rate of glycolysis and the subsequent increase in ATP/ADP ratio
closes ATP-sensitive potassium channels in the plasma membrane. Elevated potassium levels
depolarize the cell, causing opening of calcium channels and an influx of calcium through
voltage dependent L-type Ca2+.channels. Finally, an increase in the intracellular free calcium
concentration triggers the release of insulin.
Insulin secretion after glucose stimulation is biphasic. The first phase of insulin
secretion is a rapid release (5–10 min) of preformed insulin while the second, prolonged,
phase is exocytosis of newly synthesized insulin. While glucose is the most potent stimulator,
insulin secretion can also be triggered by increased concentration of some amino acids, such
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as leucine, arginine, and lysine, and gastrointestinal hormones e.g. glucose-dependent
insulinotropic peptide, and glucagon-like peptide-1 (Vilsboll and Holst 2004).
2.3 Regulation of energy homeostasis
2.3.1 Overview
The maintenance of energy homeostasis is critical for the survival of all species (Alberts et
al., 1994). In humans and mice, several complex but nevertheless very similar mechanisms
regulate energy intake and energy expenditure. ATP is the major energy currency molecule in
the cell. All living cells need to maintain a relatively high concentration of ATP and this is
achieved by adjusting the rate of ATP production to match the rate of ATP utilization. In
eukaryotes, mitochondria are responsible for the ATP synthesis through OXPHOS (Fig. 5.).
ATP production is controlled via the action of several key regulators e.g. AMPK, PGC-1
and sirtuin 1 (SIRT1).
2.3.2 Regulation of food intake
The food intake is controlled by signals from the periphery that influence the central nervous
system. The chief brain area involved in the control food intake is the arcuate nucleus (ARC)
of hypothalamus (Cone et al., 2001). Satiation signals such as cholecystokinin, glucagon-like
peptide-1, peptide tyrosine-tyrosine and ghrelin (Strader and Woods 2005; Valassi et al.,
2008) which are secreted from the gastrointestinal tract during the meal reach the nucleus of
the solitary tract in the caudal brainstem via the vagus nerve. From the nucleus of the solitary
tract, afferent fibers project to ARC where satiety signals interact with adiposity signals.
These adiposity signals are mediated by leptin and insulin which enter the brain across the
blood-brain barrier. Neurons in ARC synthesize proopiomelanocortin, neuropeptide Y and
agouti-related peptide. Proopiomelanocortin is cleaved to -melanocyte-stimulating hormone
which binds to melanocortin 3 and 4 receptors in other hypothalamic areas to reduce food
intake. Agouti-related peptide is an antagonist of melanocortin 3 and 4 receptors and
therefore counteracts the effects of melanocyte-stimulating hormone. In addition,
neuropeptide Y binds to so-called Y receptors to stimulate food intake. ARC neurons are
indirectly or directly sensitive to the action of satiation signals. The effects of adiposity
signals, ghrelin and nutritional state on food intake are mediated by hypothalamic AMPK
which modulates the expression of neuropeptides (Minokoshi et al., 2008). For example both
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fasting and ghrelin activate AMPK which increases food intake (Andersson et al., 2004;
Minokoshi et al., 2004; Minokoshi et al., 2008) while feeding, leptin and insulin inhibit
AMPK, leading to suppression of food intake.
2.3.3 Cellular respiration
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Figure 5. Cellular respiration in the mitochondrion.
Cellular respiration is a mitochondrial process in which the chemical energy of food is
released and captured in the form of ATP in the presence of oxygen (Fig. 5) (Alberts et al.,
1994). Glucose, amino acids and FFAs can all be used as fuels in cellular respiration. The
breakdown of glucose and FFAs through glycolysis and -oxidation, respectively, generates
acetyl-CoA which is then oxidized to carbon dioxide in citric acid cycle in the mitochondrial
matrix (also known as Krebs or tricarboxylic acid cycle). Amino acids can also enter the
citric acid cycle after they have been converted to various intermediates of the citric acid
cycle. The energy gathered in oxidation reactions in the citric acid cycle is conserved as the
reducing equivalents NADH and FADH2 which are oxidized in the mitochondrial respiratory
chain to form ATP via OXPHOS. The mitochondrial respiratory chain is composed of five
enzyme complexes (I-V) embedded in the inner mitochondrial membrane and of two electron
carriers, ubiquinone and cytochrome c. The reducing equivalents, NADH and FADH2, enter
into the mitochondrial respiratory chain by complex I and complex II, respectively. From
there, the electrons are transferred downhill to ubiquinone, complex III, cytochrome c,
complex IV through sequential reduction-oxidation reactions. The ultimate destination for the
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electrons is molecular oxygen which is reduced to two molecules of water. The free energy
liberated in this process is used to pump protons from mitochondrial matrix to inner
mitochondrial membrane by complexes I, III and IV. The influx of the protons back to
mitochondrial matrix through complex V (ATP synthase) allows phosphorylation of ADP
into ATP. However, not all of the energy liberated in the respiratory chain is coupled to ATP
synthesis; some is consumed by proton leak reactions in which protons pumped out of the
mitochondrial matrix are able to pass back into the mitochondria through proton conductance
pathways in the inner membrane which bypass ATP synthase (Brand 1990). This means that
some of the energy derived from the oxidation of food is dissipated and released as heat. The
uncoupling proteins (UCPs) are mitochondrial inner membrane proteins that can dissipate the
proton gradient before it can be used to provide the energy for OXPHOS (Echtay 2007).
2.3.4 The key regulators of energy expenditure
2.3.4.1 5’-AMP-activated protein kinase
AMPK  is  a  cellular  energy  sensor  that  is  found  in  all  eukaryotic  cells.  AMPK  is  a
heterotrimeric enzyme consisting of a catalytic -subunit and regulatory - and -subunits
(Hardie et al., 1998; Winder 2001). In mammals, each subunit has two or three isoforms
designated as 1, 2, 1, 2, 1, 2 and 3. All possible combinations of these isoforms
appear to be expressed. The -subunits contain an N-terminal protein kinase catalytic
domain, a central autoinhibitory region and a C-terminal domain involved in binding of
regulatory subunits (Fig. 6). The -subunits contain a glycogen-binding domain, the function
of which is not clear, but it is involved in the association of AMPK with glycogen particles
(Fig. 6). The -subunits also contain a domain participating in the formation of complexes
with  -  and  -subunits.  The  -subunits  contain  four  tandem  repeats  of  a  motif  known  as  a
cystathionine beta synthase domain (Fig. 6). These domains represent the binding sites for
regulatory nucleotides AMP and ATP.
AMPK is activated by an increase in the AMP/ATP ratio in mammals (Hardie et al.,
2003). AMP activates AMPK by three mechanisms. AMP allosterically activates AMPK
through the binding to its -subunit. In addition, AMP can stimulate phosphorylation of a
critical threonine residue (Thr-172) in the activation loop of catalytic -subunit by an
upstream kinase LKB1 (Fig. 6). Furthermore, AMP inhibits dephosphosphorylation of Thr-
172 by protein phosphatases. These effects of AMP are antagonized by the high
concentrations of ATP. The activators of AMPK are glucose deprivation, ischemia, hypoxia
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and oxidative stress that interfere with ATP production. In addition, exercise and muscle
contraction activate AMPK by increasing ATP consumption (Winder and Hardie 1996;
Hutber et al., 1997).
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Figure 6. Structure of AMPK subunits. GB, Glycogen binding domain and CBS,
cystathionine beta synthase domain.
AMPK controls energy homeostasis by increasing energy intake and energy
expenditure. Once activated, AMPK initiates cellular responses aimed at restoring the ATP
levels. AMPK enhances energy expenditure by activating pathways producing ATP, such as
fatty acid oxidation, glucose uptake and glycolysis. One of the important functions of AMPK
is the regulation of lipid metabolism through its ability to control the intracellular content of
malonyl-CoA. AMPK phosphorylates and inhibits both isoforms of ACC (ACC1 and ACC2),
which catalyze the formation of malonyl-CoA from acetyl-CoA (Abu-Elheiga et al., 1995),
leading to reduced malonyl-CoA synthesis (Winder and Hardie 1996). In addition, AMPK
stimulates malonyl-CoA degradation by phosphorylating and activating malonyl-CoA
decarboxylase (Saha et al., 2000). A reduced level of malonyl-CoA decreases the rate of fatty
acid synthesis and this relieves CPT-I from its inhibition resulting in increased fatty acid
oxidation. In several tissues, AMPK is known to inhibit fatty acid synthesis also by reducing
the expression of ACC1, fatty acid synthase and sn-glycerol-3-phosphate acyltransferase
(Woods et al., 2000; Zhou et al., 2001). The mechanism by which AMPK exerts its actions
on mitochondrial biogenesis in skeletal and cardiac muscle seems to depend on the activation
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of PGC-1 and nuclear respiratory factor (NRF) 1 (NRF-1) (Bergeron et al., 2001; Zong et
al., 2002). AMPK suppresses lipolysis by phosphorylating and inhibiting HSL (Daval et al.,
2006). AMPK also regulates several aspects of glucose metabolism. It stimulates glucose
uptake in skeletal muscle by activating GLUT4 translocation in resting muscle (Merrill et al.,
1997; Koistinen et al., 2003). This effect seems to be mediated via inhibitory phosphorylation
of AS160 (Sano et al., 2003). AMPK stimulates glucose utilization by activating the
transcription of HKII (Stoppani et al., 2002), by phosphorylating and activating
phosphofructokinase 2 (Marsin et al., 2000) and by increasing the activity of PDH (Smith et
al., 2005). In line with the role of AMPK as an intracellular energy gauge, AMPK reduces
energetically expensive processes such as gluconeogenesis and glycogen synthesis by
downregulating the expression of the key gluconeogenic enzymes (G6Pase and PEPCK)
(Lochhead et al., 2000) and phosphorylating the rate-limiting enzyme, glycogen synthase
(Miyamoto et al., 2007), respectively.
2.3.4.2 Peroxisome proliferator activated receptor  co-activator 1
PGC-1 is a member of a small family of transcriptional coactivators including PGC-1,
PGC-1 and PGC-1-related coactivator which all share common functions in the regulation
of mitochondrial biogenesis and oxidative metabolism (Andersson and Scarpulla 2001).
Human PGC-1 is mapped to chromosome 4p15 (Esterbauer et al., 1999) and it encodes
about 90 kDa protein containing an N-terminal transcriptional activation domain including a
major nuclear hormone receptor interacting LXXLL motif, a central regulatory/repression
domain and C-terminal RNA-binding and arginine-serine (RS) rich domains (Fig. 7)
(Puigserver and Spiegelman 2003). Since it is a transcriptional coactivator, PGC-1 interacts
directly with several transcription factors, such as nuclear receptors which bind to the DNA
promoter regions in the nucleus.
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Figure 7. Architecture of PGC-1 protein.
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Transcription of PGC-1 is induced by exercise (in muscle), cold exposure (in BAT and
skeletal muscle), fasting (in liver) and energy demand. The effect of exercise on PGC-1
expression is mediated by CREB (Herzig et al., 2001), myocyte enhancement factor 2 (MEF-
2) (Handschin et al., 2003) and AMPK (Fig. 8) (Terada et al., 2002). The induction of PGC-
 transcription by cold and fasting is accomplished by increased cAMP levels which
activate CREB (Fig. 8) (Gomez-Ambrosi et al., 2001; Herzig et al., 2001).
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Figure 8. Function of PGC-1 in skeletal muscle (modified from (Scarpulla 2008)).
CaMKIV, calcium/calmodulin-dependent protein kinase IV and mt, mitochondrial.
The activity and stability of PGC-1 are also affected by post-translational
modifications. Phosphorylation of PGC-1 by stress-activated p38MAPK in the repression
domain increases protein stability and the transcriptional activity of PGC-1 (Fig. 7). Fasting,
cytokines and oxidative stress elicit their effect on PGC-1 through this mechanism
(Puigserver et al., 2001; Cao et al., 2005; Kim et al., 2006). In contrast, phosphorylation of
PGC-1 by glycogen synthase kinase 3  (GSK-3) targets PGC-1 protein to ubiquitin-
mediated proteolysis iniated by E3 ubiquitin ligase SCFCdc4 (Olson et al, 2008). AMPK also
phosphorylates PGC-1 resulting in a more active protein (Fig. 7) (Jager et al., 2007). PPAR
increases PGC-1 protein levels in the absence of any increase in PGC-1 mRNA levels
(Hancock et al, 2008) and fasting-induced SIRT1, class III histone deacetylase, deacetylates
PGC-1 leading to an increase in gluconeogenic action of PGC-1 (Fig. 7) (Rodgers et al.,
2005). In addition, methylation of PGC-1 by protein arginine methyltransferase I (PRMT1)
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at C-terminus has been observed to be essential for the coactivator function of PGC-1 (Fig.
7) (Teyssier et al., 2005). In contrast, insulin inhibits PGC-1 through Akt which
phosphorylates PGC-1 at the RS domain (Fig. 7) (Li et al., 2007; Rodgers et al., 2005).
Adaptations to exercise include induction of mitochondrial biogenesis (Scarpulla 2002),
fatty acid oxidation (Vega et al., 2000), OXPHOS (Mootha et al., 2003)), glucose uptake and
fiber type switching (Puigserver and Spiegelman 2003), processes which are all stimulated by
PGC-1 (Fig. 8). The effect of PGC-1 on mitochondrial biogenesis is mainly mediated by
NRF-1, NRF-2 and estrogen-related receptor  (ERR) (Fig. 8) (Scarpulla 2002; Schreiber et
al., 2004). PGC-1 stimulates fatty acid oxidation through ERR and PPAR, both of which
activate the key enzyme(s) in the -oxidation of fatty acids (Fig. 8) (Vega et al., 2000; Huss
and Kelly 2004). Exercise-induced PGC-1 stimulates the conversion of muscle fibers from
type II (fast twitch) to type I (slow twitch) i.e. to fibers having a high oxidation capacity via
MEF-2 (Handschin et al., 2003). PGC-1 increases the expression of GLUT4 mainly via
MEF-2 in skeletal muscle and stimulates glucose uptake (Michael et al., 2001) (Fig. 8). In the
liver, PGC-1 is induced in the fasted state. Once PGC-1 is induced, it binds and coactivates
forkhead box O1, hepatocyte nuclear factor (HNF) 4 (HNF-4) and the glucocorticoid receptor
to increase the expression of gluconeogenic genes (G6Pase and PEPCK) (Puigserver et al.,
2003; Rhee et al., 2003). The stimulation of fatty acid oxidation is mediated via ERR and
PPAR coactivation similarly to the situation in skeletal muscle (Vega et al., 2000; Louet et
al., 2002; Huss and Kelly 2004). PGC-1 also activates CYP7A1, the rate-limiting gene in
bile acid synthesis (Shin et al., 2003) and represses low-density lipoprotein (LDL) receptor
(LDLR) gene expression (Jeong et al., 2009). Therefore PGC-1 is also involved in the
control of cholesterol homeostasis. In BAT in rodents, cold exposure strongly induces the
expression of PGC-1, with the consequence of the stimulation of heat production through
UCP1 (Puigserver et al., 1998).
2.3.4.3 Sirtuin 1
Sirtuins are a class of NAD+-dependent protein deacetylases which utilize the cofactor NAD+
to deacetylate lysine residues of protein substrates (Blander and Guarente 2004). Of the seven
mammalian sirtuins (sirtuin 1-7), SIRT1 has been most extensively studied. SIRT1 is induced
by elevated  concentrations  of  NAD and/or  the  ratio  of  NAD/NADH (Revollo  et  al.,  2004).
Fasting, exercise and oxidative stress induce SIRT1, most likely elevating the NAD/NADH
ratio.
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SIRT1 participates in the control of energy expenditure. It increases the activity of PGC-1
through deacetylation. In the liver, fasting-induced SIRT1 stimulates PGC-1 which evokes
an increase in gluconeogenesis and a suppression of glycolysis (Rodgers et al., 2005). In
WAT, SIRT1 suppresses adipogenesis and enhances the release of FFA through lipolysis by
repressing PPAR (Picard and Auwerx 2002; Picard et al., 2004). In vitro studies have
revealed that SIRT1 has a possible regulatory role in the insulin signalling pathway since
inhibition of SIRT1 reduces insulin-induced Akt and insulin receptor substrate-2 protein
tyrosine phosphorylation (Zhang 2007). In mice, treatment with the SIRT1 activator,
resveratrol, has been shown to result in beneficial changes in glucose and energy metabolism.
Resveratrol increases mitochondrial number and activity in the liver, skeletal muscle and
BAT, improves aerobic capacity, enhances energy expenditure and is protective against high-
fat diet-induced insulin resistance through SIRT-mediated induction of PGC-1 and AMPK
(Baur et al., 2006; Lagouge et al., 2006).
2.4 Regulation of cholesterol homeostasis
2.4.1 Overview
Fecal bile acids and neutral
sterols
Absorption
Liver
Synthesis
Intestine
Dietary
cholesterol
Biliary
cholesterol
Extrahepatic
tissues
Figure 9. Cholesterol homeostasis.
Cholesterol is an essential constituent of mammalian cellular membranes and a precursor for
the  synthesis  of  steroid  hormones,  vitamin  D and  bile  acids  (Murray  et  al.,  1993).  Humans
and mice exhibit major differences in cholesterol metabolism but cholesterol homeostasis is
similarly achieved by controlling cholesterol biosynthesis, cholesterol absorption, cholesterol
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conversion to bile acids and excretion of bile acids in both species (Fig. 9) (Dietschy et al.,
1993). Cholesterol in the body is derived from two sources, hepatic de novo synthesis and the
diet.  Cholesterol is  ultimately eliminated from the body by the conversion to bile acids and
secretion into bile.
Cholesterol is transported in the circulation by lipoproteins which are classified
according to their density and composition: 1) chylomicrons, 2) VLDL, 3) intermediate-
density lipopoteins (IDL), 4) LDL and 5) high-density lipoprotein (HDL) (Murray et al.,
1993). In humans, the proportion of HDL cholesterol from total cholesterol is 20% of total
cholesterol whereas LDL cholesterol represents more than 50% of total cholesterol (Argmann
et al., 2006). In contrast, mouse HDL cholesterol varies between 65 to 75% of total
cholesterol and correspondingly the LDL cholesterol fraction is only between 10 to 20 %.
Lipoproteins contain a variety of lipids such as TGs, phospholipids, cholesterol and
cholesteryl esters (CEs) (Murray et al., 1993). Chylomicrons and VLDL particles are TG-rich
particles whereas LDL and HDL particles contain predominantly cholesterol and
phospholipids, respectively. IDL particles have equal amounts of CEs, TGs and
phospholipids.
Chylomicrons transport dietary cholesterol and TG absorbed from the small intestine to
the liver (Murray et al., 1993). In the circulation, TGs of chylomicrons are hydrolyzed by
LPL leading to the formation of chylomicron-remnants which are cleared by the liver through
the LDLR related protein. The cholesterol entering the liver can then be used for lipoprotein
formation, bile acid synthesis, secretion to bile, or storage as CEs.
The assembly of VLDL is a two step lipidation process (Olofsson et al., 2000; Adiels et
al., 2008)]. In the first step, apoliporotein B100 is lipidated by microsomal transfer protein
which  leads  to  the  formation  of  pre-VLDL.  In  the  second  step,  pre-VLDL  is  converted  to
VLDL by ADP ribosylation factor-1. In the circulation, TG-rich VLDLs are hydrolyzed by
LPL and converted to IDL. The subsuquent hydrolysis of IDL particles by hepatic lipase
produces LDL particles which deliver cholesterol to the extrahepatic tissues where the uptake
of cholesterol is facilitated by LDLRs. LDL particles are catabolized mainly by hepatic
uptake via LDLRs. The rate of hepatic LDL clearance is significantly greater in mice than in
humans (Dietschy and Turley 2002).
The biosynthesis of HDL begins in the liver where apolipoprotein A-I interacts with
ATP binding cassette protein A1 (ABCA1) and apolipoprotein A-I is then secreted into the
circulation as a lipid-poor particle (Rader 2006). These particles then recruit more
phospholipids and free cholesterol from peripheral tissues through the action of ABCA1,
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which is expressed on the surfaces of macrophages in the arterial wall, forming nascent HDL2
particles. Lecithin:cholesterol acyltransferase within nascent-HDL particles esterifies free
cholesterol resulting in the formation of mature small HDL3-particles. The fusion of two
small HDL3 particles by phospholipid transfer protein generates one larger size HDL2
particle. In mice, the expression of phospholipid transfer protein is significantly higher than
in humans. Hepatic lipase and endothelial lipase degrade HDL2 lipoproteins to HDL remnant
particles which are cleared from the circulation by hepatic class B type 1 scavenger receptor
(SR-BI). The cholesterol acquired from peripheral tissues by HDLs can be also transferred to
VLDLs and LDLs via the action of HDL-associated enzyme, cholesteryl ester transfer protein
(CETP), in humans but not in mice which do not express CETP (Hogarth et al., 2003). The
function of CETP allows peripheral cholesterol to be returned to the liver as LDL particles
via LDLRs.
2.4.2 Cholesterol synthesis
The major part of cholesterol is synthesized in the liver. The murine liver is relatively more
important as a site for cholesterol synthesis than its human counterpart (Dietschy and Turley
2002). Cholesterol biosynthesis can be divided into five steps (Fig. 10): 1) synthesis of
mevalonate from acetyl-CoA, 2) formation of isoprenoid units, 3) formation of squalene from
six isoprenoid units 4) conversion of squalene to lanosterol, and 5) conversion of lanosterol to
cholesterol either through desmosterol or demethyl- or methylsterols (Murray et al., 1993).
The rate-limiting step is the formation of mevalonate from 3-hydroxy-3-methylglutaryl-CoA,
catalyzed by 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) (Goldstein and Brown
1990). After the synthesis, acyl CoA:cholesterol acyltransferase 2 (ACAT2) esterifies
cholesterol to CEs which can be stored or used in the formation of lipoproteins (Chang et al.,
2001).
The rate of cholesterol formation is highly responsive to changes in the intracellular
cholesterol level in humans and mice. This feedback regulation is mediated primarily by
changes  in  the  amount  and  activity  of  HMGCR  which  is  controlled  at  four  levels.  First,
degradation of HMGCR is stimulated by cholesterol whose binding to a transmembrane
sterol-sensing domain activates the degradation of the enzyme via the 26S proteasome
(DeBose-Boyd 2008). Second, sterol regulatory element binding proteins (SREBPs) activate
the transcription of HMGCR and other genes involved in cholesterol biosynthesis (Brown
and Goldstein 1997). When cholesterol levels are low, SREBPs induce HMGCR but
cholesterol accumulation decreases the expression of SREBPs. Third, the rate of translation
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of HMGCR mRNA is inhibited by sterol and nonsterol end-products of mevalonate
metabolism and dietary cholesterol (DeBose-Boyd 2008). In addition to feedback regulation,
HMGCR activity is inhibited by phosphorylation through the action of AMPK when the
cellular ATP content is low (Clarke and Hardie 1990). Hepatic de novo synthesis and
intestinal absorption are reciprocally regulated, e.g. when cholesterol absorption decreases,
cholesterol synthesis increases and vice versa (Grundy et al., 1969).
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Figure 10. Cholesterol biosynthesis in mammals.
2.4.3 Cholesterol absorption
Cholesterol absorbed from the intestinal lumen originates from three sources, diet, bile and
turnover of intestinal epithelium (Vuoristo and Miettinen 2000). The amount of dietary
cholesterol absorbed varies between 30-70% in humans and mice (Dietschy and Turley
2002). Only free cholesterol can be effectively absorbed and thus, CEs are de-esterified by
the pancreatic cholesterol esterase (Vuoristo and Miettinen 2000). Cholesterol, which is
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insoluble in an aqueous environment, needs to be incorporated into bile acid micelles prior to
absorption. The micelles are then transported to the brush border membrane of enterocytes
where cholesterol passes through a diffusion barrier that is located at intestinal lumen-
enterocyte membrane interface. Cholesterol absorption was previously thought to be simple
passive diffusion process. However, cholesterol uptake transporter protein, Niemann–Pick
C1-like 1 protein (NPC1L1), was recently identified in the jejunum (Altmann et al., 2004).
SR-BI and CD36 are the two other transporters that facilitate cholesterol transport (Nauli et
al., 2006; Labonte et al., 2007). In addition to cholesterol uptake transporters, there are three
cholesterol efflux transporters in the brush border membrane, ABCA1, ATP binding cassette
protein G5 (ABCG5) and ATP binding cassette protein G8 (ABCG8) which excrete
cholesterol back into the intestinal lumen and limit cholesterol absorption (Vuoristo and
Miettinen 2000). After absorption, cholesterol is esterified by ACAT2 to CEs, incorporated
into  chylomicron  particles  through  the  action  of  the  microsomal  tranfer  protein   and
transported via the lymph to the circulation.
Any factor that can change cholesterol transport from intestinal lumen to the enterocyte
can influence intestinal cholesterol absorption (Vuoristo and Miettinen 2000). The genetic
control of cholesterol absorption is clearly evident. For example mouse strains display
significant differences in absorption rates when fed a high cholesterol diet (Carter et al.,
1997), and human and mouse studies have also shown a high variation in cholesterol
absorption efficiency between different human individuals (25 to 75%) and mice (22 to 66%)
(Miettinen and Kesaniemi 1989; Schwarz et al., 2001). Dietary fiber, especially viscous fiber,
inhibits cholesterol absorption by disturbing micellar solubilization and/or increasing the
diffusion barrier (Vuoristo and Miettinen 2000). In addition, dietary plant sterols such as
those found in vegetable oils, inhibit cholesterol absorption by displacing cholesterol from
micelles and inducing cholesterol efflux (Plat and Mensink 2002). Changes in hepatic output
and  the  size  of  bile  acid  pool  markedly  influence  cholesterol  absorption.  For  example,  the
expansion of the total bile acid pool inhibits cholesterol absorption by decreasing the
expression of NPC1L1 in mice (Ratliff et al., 2006).
2.4.4 Cholesterol elimination through bile acid synthesis
In mammals, liver controls the elimination of cholesterol from the body. The hepatic
formation of bile acids is mainly accomplished through the neutral/classic pathway in humans
and mice. The rate-limiting enzyme responsible in this pathway is hepatic CYP7A1 (Russell
and  Setchell  1992;  Fuchs  2003).  The  second  pathway  termed  as  the  acidic  (or  alternative)
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pathway is initiated by sterol 27-hydroxylase (CYP27A1). The major bile acids in humans
are cholic acid and chenodeoxycholic acid. Since murine chenodeoxycholic acid is converted
to muricholic acid, cholic acid and muricholic acid are the main bile acids found in rodents
(Houten  et  al.,  2006).  After  synthesis,  bile  acids  are  conjugated  with  taurine  or  glycine  in
humans but only taurine conjugates exist in mice. Bile acids are exported from hepatocytes to
biliary canaliculi by a bile salt export pump, secreted into bile and stored in the gallbladder
(Russell and Setchell 1992; Fuchs 2003). After the meal, the gallbladder secretes bile into the
intestine where bile acids are converted to secondary and tertiary bile acids by intestinal
bacteria. Most bile acids are reabsorbed in the ileum by the action of apical Na+-dependent
bile acid transporter or ileal bile acid binding protein and transported back to the liver via the
portal circulation. Hepatic uptake of bile acids is mainly facilitated by Na+-taurocholate
cotransporting polypeptide (NTCP) and Na+-independent organic anion transporting
polypeptide (OATP1) (Meier and Stieger 2002). The function of bile acids is to emulsify
lipids in the intestine and to act as signalling molecules (Hylemon et al., 2009).
The conversion of cholesterol into bile acids is controlled by CYP7A1 which is mainly
regulated at the gene transcriptional level by bile acids, nutrients, cytokines and hormones
(Jelinek et al., 1990; Fuchs 2003). In mice, dietary cholesterol activates CYP7A1
transcription through liver X receptor  (LXR) whereas the human CYP7A1 promoter lacks
the LXR binding site (Chiang et al., 2001). Important activators of CYP7A1 transcription
are HNF-4, COUP-TFII, -fetoprotein transcription factor, liver receptor homolog 1 and
PGC-1 in humans and rodents (Galarneau et al., 1996; Nitta et al., 1999; Hayhurst et al.,
2001; Shin et al., 2003). PGC-1 activates CYP7A1 transcription by increasing HNF-4-
mediated transactivation of CYP7A1 (De Fabiani et al., 2003; Shin et al., 2003). One well-
conversed repression mechanism between species is the activation of small heterodimer
partner by bile-acid induced farnesoid X receptor (FXR). Small heterodimer partner inhibits
HNF-4-, -fetoprotein transcription factor- or liver receptor homolog 1-mediated
transactivation of CYP7A1 transcription (Makishima et al., 1999; Lu et al., 2000). The
transcription of CYP27A1 is also suppressed by bile acids but this effect is less potent than
that occuring at the CYP7A1 gene (Chiang et al., 2001).
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3 AIMS OF THE STUDY
The main purpose of this study was to investigate the effects of activated and inactivated
polyamine catabolism on glucose, energy and lipid metabolism in mice.
The specific aims were:
1. To characterize the metabolic phenotype of SSAT mice and to elucidate the
molecular mechanism explaining the phenotype (I)
2. To investigate the effect of activated polyamine catabolism on cholesterol and
bile acid metabolism in SSAT mice and to determine the molecular mechanism
leading to these changes (II)
3. To characterize the metabolic phenotype of SSAT-KO mice (III)
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4 MATERIALS AND METHODS
4.1 Animals (I-III)
The mice used in these studies were as follows (the mouse strain is shown in parentheses): a)
transgenic mice overexpressing SSAT under endogenous SSAT promoter (DBA/2 x Balb/c)
(Pietilä et al., 1997), b) Hairless (hr/hr) or normally haired (hr/+) (HsdOla) mice purchased
from Harlan, UK and c) SSAT-KO mice (C57BL/6J) generated in collaboration with
Karolinska Institute, Sweden. The animals were housed under standard conditions and were
fed a regular laboratory chow (R3, Lactamin AB, Stockholm, Sweden). The study protocols
were approved by the Animal Care and Use Committee of the University of Kuopio and the
Provincial government. Generation of SSAT-KO mice was performed as followed. The
SSAT targeting vector (Niiranen et al., 2002) was electroporated into the mouse RW-4
embryonic  stem cell  line.  The  correctly  targeted  SSAT-KO embryonic  stem cell  clone  was
injected into C57Bl/6J blastocysts which were transplanted into pseudopregnant females. The
SSAT-KO mice were backcrossed in the C57BL/6J mouse strain for at least six generations
to dilute the 129/SvJ genetic background originating from embryonic stem cells.
4.2 Polyamine analogues, antibodies and primers (I-III)
DENSPM was synthesized in the University of Kuopio as previously published (Rehse et al.,
1990). DFMO was a gift from Ilex Oncology Inc, USA. The antibodies used in these studies
were  as  follows:  PGC-1 (Millipore,  Billerica,  MA,  USA),  HNF-4 (Santa  Cruz
Biotechnology,  Inc.,  Santa  Cruz,  CA,  USA),  LXR (Abcam,  UK),  FXR  (Santa  Cruz
Biotechnology, Inc., Santa Cruz, CA, USA), phosphorylated -subunit of AMPK (Thr172)
(Cell Signaling Technology Inc, Danvers, MA, USA), SIRT1 (Millipore, Billerica, MA,
USA), dually phosphorylated p38 MAPK (Thr180/Tyr182) (Cell Signaling Technology Inc,
Danvers,  MA,  USA),  PRMT1  (Cell  Signaling  Technology  Inc,  Danvers,  MA,  USA),
phosphorylated Akt (Ser473) (Cell Signaling Technology Inc, Danvers, MA, USA), Akt (Cell
Signaling  Technology  Inc,  Danvers,  MA,  USA),  PI3K  (Cell  Signaling  Technology  Inc,
Danvers, MA, USA), phosphorylated GSK-3 (Ser21/9) (Cell Signaling Technology Inc,
Danvers, MA, USA), GSK-3 (Cell Signaling Technology Inc, Danvers, MA, USA), PPAR
(Santa  Cruz  Biotechnology,  Inc.,  Santa  Cruz,  CA,  USA),  and  actin  (Santa  Cruz
Biotechnology, Inc., Santa Cruz, CA, USA). Quantitative RT-PCR primers and probes were
designed using Assay-by-Design system from Applied Biosystems, USA.
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4.3 Data and statistical analyses (I-III)
Affymetrix data was analyzed using Affimetrix Microarray Suite 5.0, GenMAPP (Dahlquist et
al., 2002) and MAPPFinder (Doniger et al., 2003) software. Statistical analysis was performed
with Student's two-tailed t-test when applicable. In the multiple comparisons, two-way ANOVA
was used. A p value less than 0.05 was considered significant.
4.4 Analytical methods, and in vitro and in vivo experiments (I-III)
Table 1 shows methods used to measure plasma, serum, fecal or tissue metabolite concentrations
in the original publications I-III. Plasma or serum samples were taken from the saphenous or tail
vein in the fed or fasted state (12-18 h fasting). Fecal samples and tissues were collected in the
fed state. Table 2 summarizes methods or kits used in the different analyses in the original
publications I-III. Tables 3 and 4 summarize in vivo and in vitro studies performed in original
publications I-III, respectively. A detailed description of all methods is provided in the original
publications I-III given in Tables 1-4 and in the references provided in Table 2.
Table 1. Analysis of plasma, serum, fecal or tissue metabolites in publications (Publ) I-III.
ELISA, Enzyme-linked immunosorbent assay; GLC, gas-liquid chromatography and HPLC,
high pressure liquid chromatography.
Metabolite Method Equipment/Kit Publ
Plasma TG Enzymatic Microlab 200 analyzer I, III
Serum FFA Enzymatic TG detection kit (Wako) I
Plasma alkaline phosphatase Colorimetric Microlab 200 analyzer II
Plasma alanine
aminotransferase
Kinetic Microlab 200 analyzer II
Plasma glucose Enzymatic Microfluorometry I, III
Plasma insulin ELISA Rat insulin kit (Chrystal Chem) I, III
Plasma leptin ELISA Mouse leptin kit (Chrystal Chem) I
Serum -hydroxybutyrate Enzymatic Hitachi 717 analyzer I
Plasma glycerol Enzymatic Microfluorometry I
Plasma total cholesterol Enzymatic Microlab 200 analyzer III
Plasma, liver and fecal
total cholesterol
GCL Gas chromatography II
Serum HDL cholesterol Enzymatic Hitachi 717 analyzer II
Plasma cholesterol precursors GCL Gas chromatography II
Plasma cholesterol
absorption markers
GCL Gas chromatography II
Serum total bile acids Enzymatic Spectrophotometry II
Fecal bile acids GCL Gas chromatography II
Tissue polyamine content HPLC HPLC I, III
Adipocyte ATP content Chemiluminesence ATPlite one step kit (Perkin Elmer) I
Tissue DENSPM content HPLC HPLC III
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Table 2. Methods used in the original publications (Publ) I-III.
Method                          Reference/Kit Publ
Magnetic resonance imaging (Harrington et al., 2002) I
Tissue TG content using glycerol assa (Wieland 1974)1] I
Indirect calorimetry (McLean and Tobin 1990) I
Telemetric core temperature and
activity measurement
(Hohtola et al., 1991) I
Fatty acid oxidation (Mannaerts et al., 1979; Osmundsen 1981) I
Isolation of mitochondria (Pallotti and Lenaz 2001) I
Histology (Rantala and Lounatmaa) I-III
Macrophage staining (Leppanen et al., 1998) I
Adipocyte isolation (Rodbell 1964) I
Adipocyte cell sizing (Krotkiewski et al., 1983) I
Electron microscopy (Lounatmaa and Rantala 1991) I
Affymetrix MG-U74A-v2 chip analys Affymetrix protocols I
RNA isolation RNAeasy kit (Qiagen),
(Chomczynski and Sacchi 1987)
I, II
Mitochondrial DNA isolation (Straus 1998) I
DNAse treatment DNA freeTM kit (Ambion) I, II
cDNA synthesis High capacity archive kit (Applied Biosystem I, II
Sodium dodecyl sulfate (SDS) page (Laemmli 1970) I, II
Immunoblotting and -detection (Gallgher et al., 2008) I, II
SSAT activity (Bernacki et al., 1995) I, III
Protein concentration Bio Rad Protein Assay I-III
Double-stranded DNA amount (Giles and Myers 1964) I
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5 RESULTS
5.1 Effect of activated polyamine catabolism on glucose and energy
metabolism in mice (I)
Characteristics of body composition and white adipose tissue. After birth, female and
male SSAT mice were slightly lighter than their littermates until they were 8 weeks old while
female  SSAT  mice  tended  to  have  a  higher  body  weight  at  the  age  of  3-  to  4-months.
Activated polyamine catabolism severely reduced WAT mass (Table 5) and this was already
evident at the age of 4 weeks. Furthermore, the tissue TG content was significantly reduced
in SSAT mice. Adipocytes in SSAT mice were smaller than in wild-type mice but otherwise
the morphology of the adipocytes was normal showing typical unilocular cells (Fig. 11).
Transmission electron microscopic analysis of WAT revealed that SSAT mice had an
increased size and number of mitochondria in WAT as compared with wild-type mice (Fig.
11). The expression of the key factors regulating adipocyte differentiation, PPAR, CEBP/
and SREBP1c were increased in WAT of SSAT mice. Surprisingly, activated polyamine
catabolism caused enlargement of internal organs in female SSAT mice while adult males
exhibited only an enlarged spleens. Furthermore, lean body mass was significantly higher in
female SSAT mice as compared with female wild-type mice (Table 5). In contrast, the weight
of skin was increased both in female and male SSAT mice (Table 5).
Wild type Transgenic
TEM
Light
Microscopy
Figure 11. Morphology of WAT in SSAT and wild-type mice. TEM, transmission electron
microscopy.
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Table 5. Characteristics of female SSAT mice as compared to wild-type mice.
WAT, white adipose tissue; bw, body weight; Glc, glucose; Ins, insulin; AUC, area under the
curve; GTT, glucose tolerance test, ITT, insulin tolerance test; RQ, respiratory quotient.
Results are means ± SEM of 5-19 mice. *, p<0.05; **, p<0.01 and ***, p<0.001.
Glucose and lipid metabolism. SSAT mice had significantly reduced fasting glucose
and insulin levels (Table 5). Furthermore, SSAT mice displayed improved glucose tolerance
and increased insulin sensitivity based on glucose and insulin tolerance tests (Table 5). The
protein and mRNA levels of two important factors increasing glucose transport, PGC-1 and
AMPK, were upregulated in WAT of SSAT mice. In addition, expressions of the genes
involved in glucose phosphorylation and glucose oxidation (HKII and PDH E1 component -
subunit) were significantly increased in WAT of SSAT mice. In the fasting state, TG levels,
glycerol, 3-hydroxybutyrate and leptin levels were significantly lower in SSAT mice as
compared to wild-type mice whereas FFA levels were unaltered (Table 5).
Energy homeostasis. Activated polyamine catabolism increased oxygen consumption
(VO2) in young haired and adult hairless SSAT mice (Table 5). Consistent with the increased
energy expenditure, food intake was higher in SSAT mice than in wild-type mice (Table 5)
whereas locomotor activity was lower in SSAT mice, especially during the night-time. The
respiratory quotient (RQ) was significantly lower in the fasting and active state in SSAT mice
Parameter Wild type SSAT
Whole body WAT mass (% of bw) 26.5 ± 0.5     9.4 ± 2.8**
Lean body mass (% of bw) 60.3 ± 0.5  69.8 ± 2.8*
Skin mass (% of bw) 13.2 ± 0.3  20.8 ± 0.6*
Fasting Glc (mM) 10.3 ± 0.5        8.5 ± 0.2***
Fasting Ins (ng/ml)   0.6 ± 0.2    0.3 ± 0.1*
Glucose AUC during GTT 1913 ± 191 1320 ± 95*
Insulin sensitivity index, ITT   0.13 ± 0.02     0.22 ± 0.03*
Fasting plasma TG (mM)   1.4 ± 0.1    1.1 ± 0.1*
Fasting plasma glycerol (mM)    1.16 ± 0.12    0.88 ± 0.05*
Fasting serum 3-hydroxybutyrate (mM)    2.45 ± 0.42        0.58 ± 0.43***
Fasting plasma leptin (ng/ml)    2.9 ± 0.8    0.3 ± 0.1*
Fasting serum FFA (mM)   0.67 ± 0.05   0.72 ± 0.06
VO2 (ml/min/kg), young haired  34.2 ± 0.1     40.6 ± 0.1**
VO2 (ml/min/kg), adult hairless 22.8 ± 0.4       32.2 ± 0.4***
Food intake (g/day/mouse)   3.03 ± 0.08     4.67 ± 0.24*
RQ, active and fasting state   0.86 ± 0.01     0.82 ± 0.01*
Palmitate oxidation in WAT (pmol/µgDNA),
pooled samples
75.7 144.9
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as compared with wild-type mice (Table 5) indicating higher fatty acid oxidation in SSAT
mice. Indeed, the rate of palmitate oxidation was enhanced in isolated adipocytes of SSAT
mice (Table 5) but not in skeletal muscle and liver. Correspondingly, the expressions of the
genes involved in -oxidation of fatty acids (acyl-CoA dehydrogenases) and fatty acid uptake
(CD36, fatty acid transport protein 1 and adipocyte-specific fatty acid-binding protein 4)
were elevated in WAT of SSAT mice. With respect to the key factors regulating fatty acid
oxidation, PGC-1, ERR and PPAR, were unregulated in WAT of SSAT mice. The genes
governing fatty acid synthesis (e.g. ACC1 and fatty acid synthase) and lipolysis (HSL) were
upregulated in WAT of SSAT mice.
Putrescine
Spermidine
Spermine
Ornithine
ODC
SSAT
PAO
SSAT
PAO
Spm
synthase
AdoMet
Met
+
2 ATP
AdoMet
Met
+
2 ATP
dcAdoMet
dcAdoMet
AdoMetDC
AdoMetDC1.
2.
3.
4.
Acetyl-CoA
Acetyl-CoA
Fatty acid oxidation
Mitochondrial biogenesis
Uncoupling
Insulin sensitivity
AMPK
PGC-1
Spermidine
Spd
synthase
ATP
DFMO
Figure 12. Proposed molecular mechanism causing the phenotype of SSAT mice. Spd,
spermidine, Spm, spermine; Met, methionine and AdoMet, S-adenosylmethionine.
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The mechanism leading to the induction of peroxisome proliferator activated
receptor  co-activator 1. Our mechanistic studies demonstrated that the factor connecting
activated polyamine catabolism and PGC-1 is AMPK, i.e. both isoform expression and
protein amount of this enzyme were significantly elevated in WAT of SSAT mice. Since
AMPK is activated by the increase in the AMP/ATP ratio, we hypothesized that the enhanced
polyamine catabolism may have evoked a depletion of the ATP pool in WAT of SSAT mice
because each polyamine cycle theoretically consumes 4 ATP equivalents (2 ATP and 2
acetyl-CoA) (Fig. 1 and Fig. 12). Indeed, SSAT mice had approximately ~50 % lower ATP
concentrations in isolated adipocytes than wild-type mice. In addition, DENSPM treatment
reduced significantly ATP concentrations in isolated mouse fetal fibroblasts during nutrient
deprivation. Therefore, it is hypothesized that the depletion of ATP levels activates AMPK
which in turn induces PGC-1 in WAT of SSAT mice. (Fig. 12)
Since SSAT overexpression accelerates the rate of polyamine cycle and the overall flux
of polyamines, we tested whether a reduction in the rate of polyamine flux will increase ATP
concentrations and reverse the phenotype of SSAT mice by blocking ODC using DFMO (Fig.
12). Indeed, the lowered rate of polyamine cycle, detected by significantly decreased
putrescine concentrations in WAT of SSAT mice, elevated ATP concentrations in the
adipocytes with a concomitant increase in perigonadal WAT mass. DFMO treatment also
restored the changes in gene expression in WAT of SSAT mice to the levels resembling those
observed in wild-type mice.
5.2 Effect of activated polyamine catabolism on cholesterol homeostasis in
mice (II)
Cholesterol metabolism. During characterization of the metabolic phenotype of SSAT mice,
it  was  observed  that  mice  with  SSAT  overexpression  exhibited  low  plasma  total  and  HDL
cholesterol  levels  but  increased  serum  total  bile  acid  concentrations.  In  contrast,  fasting
plasma alkaline phosphatase and alanine aminotransferase were similar compared with wild-
type values indicating normal liver function. To determine the reasons behind these changes,
we analysed variables of cholesterol metabolism and expression of the genes involved in the
regulation of cholesterol homeostasis. Plasma cholesterol precursors were significantly
elevated in SSAT mice interpreted as evidence of increased cholesterol synthesis. This result
was verified by analyzing expression of cholesterol biosynthetic genes. Indeed, HMGCR,
squalene synthase and 7-dehydrocholesterol reductase were upregulated in the livers of SSAT
mice (Fig. 13). Since the plasma cholesterol absorption markers were lowered and expression
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of cholesterol transporters, NPC1L1 and SR-BI, were decreased in jejunum in SSAT mice
(Fig. 13), it seemed that cholesterol absorption was reduced in SSAT mice. This concept was
verified by measuring cholesterol absorption efficiency which proved to be significantly
lower in SSAT mice. Unaltered hepatic expression of LDLR and SR-BI in SSAT mice
excluded the possibility that enhanced hepatic clearance of cholesterol led to lowered
cholesterol levels in SSAT mice (Fig.13). Interestingly, we observed that hepatic expression
of ACAT2 was significantly reduced in the fed state, indicating that VLDL assembly may
have been disturbed. Moreover, expression of ABCA1, the key regulator of HDL lipidation,
was similar in SSAT mice as compared with wild-type.
Bile acid metabolism. When bile acid metabolism was investigated, it was noticed that
SSAT mice had enhanced bile acid synthesis since there were elevated expressions of the
rate-limiting genes in the neutral and acidic bile acids synthesis pathways, CYP7A1 (Fig. 13)
and CYP27A1. In contrast, hepatic bile acid transporters responsible for bile acid uptake,
NTCP and OATP1, were significantly downregulated in the fed state (Fig. 13). Intestinal bile
acid absorption was comparable to that of wild-type mice since bile acid absorption
efficiency and expression of apical Na+-dependent bile acid transporter and ileal bile acid
binding protein were unchanged (Fig. 13). Since the fecal bile acid content was increased in
SSAT mice, it appears very likely that bile acid secretion was increased. However, gene
expression studies did not reveal increase in the expression of bile salt export pump.
Cholesterol secretion to bile was not presumably increased since mRNA levels of biliary
cholesterol exporters, ABCG5 and ABCG8, remained unchanged.
The mechanism leading to increased bile acid synthesis. In order to investigate the
mechanism for the activation of main bile acid synthesis pathway, we analyzed hepatic
expression of factors activating or repressing CYP7A1 transcription (PGC-1, HNF-4,
LXR, FXR, pregnane X receptor, constitutive androstane receptor, SREBP1c, PPAR,
histone deacetylase 7 and HNF-6). Gene expression analyses did not reveal any marked
alterations in the expression of these factors. Therefore, the next step was to analyze the
protein levels of these factors. The results showed that the protein levels of the key activator
of CYP7A1, PGC-1, were significantly elevated in SSAT mice in the fasting and fed state
(Fig. 13). As mRNA levels of PGC-1 were unchanged in the livers of SSAT mice, it was
concluded that post-translational modification of PGC-1 most likely was responsible for the
elevated PGC-1 protein levels. The first candidate considered to cause this effect was
AMPK because enhanced polyamine catabolism is known to induce AMPK in WAT of
SSAT mice by depleting the ATP pool. Surprisingly, despite a slightly decreased ATP pool in
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the liver (unpublished data), phosphorylated AMPK levels were reduced in the fasting state in
the livers of SSAT mice while protein levels were unchanged in the fed state.
As more active and/or stable PGC-1 protein is achieved through deacetylation by
SIRT1, phosphorylation by p38MAPK, inhibition of phosphorylation by GSK-3 or
methylation PRMT1, the protein levels of these modulators were analyzed. PRMT1, SIRT1
and phosphorylated, i.e. active, p38MAPK and GSK-3 were unaltered in the fed state
whereas the protein amounts of inhibitor of PGC-1, phosphorylated and i.e. active Akt, were
significantly reduced in the livers of SSAT mice in the fed state (Fig. 13). A reduction in the
activity of Akt may lead to decreased PGC-1 protein phosphorylation resulting in a more
stable protein as proposed by Rodgers and coworkers (Rodgers et al., 2005). The effect of
activated polyamine catabolism on phosphorylation of Akt seems to be Akt protein
degradation- and PI3K pathway-independent since protein levels of total Akt and an upstream
regulator of Akt, PI3K, were not altered in SSAT mice. Since it is well-established that a
SSAT activator, DENSPM, can reduce phosphorylation of Akt in glioblastoma (Jiang et al.,
2007) and breast cancer cells (Nair et al., 2007), we investigated whether activated polyamine
catabolism could cause this effect also in hepatocytes. Indeed, a reduction in the protein
amount of phosphorylated Akt was detected in DENSPM-treated human hepatoma HepG2
cells at 48 h as compared with untreated cells.
Figure 13. Main findings in cholesterol metabolism in SSAT mice. Chol, cholesterol;
FDFT1, squalene synthase; DHCR7, 7-dehydrocholesterol reductase; BA, bile acid; pAkt,
phosphorylated Akt; ASBT, Apical Na+-dependent bile acid transporter and I-BABP, ileal
bile acid binding protein.
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5.3 Effect of deficiency of polyamine catabolism on the metabolic
phenotype in mice (III)
Polyamine homeostasis. In order to investigate whether deficiency of polyamine catabolism
has an opposite effect on metabolism as compared with activated polyamine catabolism, we
characterized the metabolic phenotype of SSAT-KO mice. However, first the effect of
polyamine catabolism deficiency on polyamine homeostasis was investigated. The absence of
inducible SSAT activity was initially confirmed by carbon tetrachloride and DENSPM
treatments and as anticipated, no inducible SSAT activity was observed in SSAT-KO mice
whereas these treatments caused typical activated catabolism-caused changes in tissue
polyamine content in wild-type mice. Under basal conditions, SSAT activity was close to the
wild-type mice level in SSAT-KO mice and a small amount of N1-acetylspermidine was also
detected. The SSAT deficiency caused only minor changes in the polyamine pool since only
a slight increase in spermidine concentrations was manifested during aging in all analyzed
tissues, with the exception of the pancreas. Since activated polyamine catabolism has been
shown to cause enhanced sensitivity to the toxicity of DENSPM in SSAT mice (Alhonen et
al., 1999), it was hypothesized that SSAT deficiency confers resistance against the
DENSPM-induced harmful effects. Therefore, SSAT-KO and wild-type mice were subjected
to daily injections of DENSPM. Surprisingly, SSAT-deficient mice (median=5 day) died
approximately 3 days earlier than wild-type mice (median=8 day). The DENSPM treatment
significantly induced SSAT activity and evoked the typical changes of activated polyamine
catabolism in the polyamine concentrations in several tissues of wild-type mice. In contrast,
DENSPM did not have any effect on the tissue polyamine content in SSAT-KO mice
although  the  extent  of  DENSPM  accumulation  was  similar  in  both  genotypes.  Histological
examination  of  tissues  did  not  reveal  any  differences  between DENSPM-treated  SSAT-KO
and wild-type mice.
Body composition and energy homeostasis. SSAT deficiency did not affect body
weight when the average body weights of SSAT-KO mice were compared to those of wild-
type mice. However, a subgroup of animals having a higher body weight was observed.
Furthermore, no change in whole body WAT mass was detected in the magnetic resonance
imaging or weight of the perigonadal WAT pads. Consistent with these results, plasma leptin
levels did not differ from wild-type mice (unpublished data). Adipocyte morphology and
organ weights were similar as those encounted in wild-type mice (unpublished data) while
histological examination of kidneys of aged SSAT-KO mice revealed dilation of Bowman’s
space and tubules of inner medulla, atrophy of glomeruli and associated cells, and
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inflammation and necrosis of renal papillae. Oxygen consumption and other parameters
related to energy expenditure were not analyzed in SSAT-KO mice. However, the food intake
of these mice was observed to be rather similar to that of wild-type counterparts.
Glucose and lipid metabolism. SSAT deficiency led to the development of increased
fasting blood glucose levels after the age of 12 months. A glucose tolerance test in 16-month-
old SSAT-KO mice showed similar glucose disposal from the circulation but significantly
elevated insulin levels in SSAT-KO mice (Fig. 14). The presence of peripheral insulin
resistance was confirmed using an insulin tolerance test which displayed significantly higher
glucose  levels  in  response  to  insulin  at  all  time  points  in  SSAT-KO  mice  (Fig.  14).  The
deficiency of SSAT did not cause alterations in plasma total cholesterol and TG levels in
young or aged in SSAT-KO mice. Plasma HDL and LDL cholesterol or other parameters
involved lipid metabolism were not analyzed in SSAT-KO mice.
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Figure 14. Glucose and insulin tolerance tests in SSAT-KO and wild-type mice. Fasted 16-
month-old SSAT-KO and wild-type male mice were subjected to A) intraperitoneal glucose
tolerance (2 mg/g D-glucose) and B) insulin tolerance (0.25 mU/g insulin) tests. Results are
means ± SEM of 10-12 mice. p<0.05 and **, p<0.01.
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6 DISCUSSION
SSAT is the rate-controlling enzyme in the catabolism of polyamines (Jänne et al., 2004).
The  overexpression  or  loss  of  SSAT  is  sufficient  to  cause  the  corresponding  activation  or
deficiency of polyamine catabolism. We determined the role of polyamines and polyamine
metabolism in the regulation of glucose, energy and lipid metabolism.
Activated polyamine catabolism, white adipose tissue and body composition (Study
I). A novel finding in our study was that the endogenous SSAT promoter targeted the highest
SSAT activity into WAT. This resulted in severely reduced whole body WAT mass in young
and adult mice, a phenomenon also demonstrated by Jell and coworkers (Jell et al., 2007).
Since  the  adipocytes  of  SSAT  mice  were  smaller  but  their  number  was  unchanged,  the
reduction in WAT mass seemed to be due to diminished TG accumulation and not due to
impaired differentiation of the adipocytes. This concept was supported by the finding that the
expressions of key factors regulating adipogenesis, PPAR, CEBP/ and SREBP1c, were
upregulated in WAT of SSAT mice. Furthermore, the levels of spermidine, which has been
observed to be necessary for adipogenesis (Bethell and Pegg 1981; Vuohelainen et al., 2009),
were not reduced in WAT of SSAT mice. The reduced TG accumulation in the adipocytes of
SSAT mice was attributable to the increased expression of PGC-1, the critical regulator of
energy metabolism which is also involved in the differentiation of preadipocytes to brown
adipocytes (Puigserver and Spiegelman 2003). In WAT, the expression of PGC-1 is
normally low (Puigserver and Spiegelman 2003) but ectopic expression of PGC-1 in
adipocytes can induce a conversion of white adipocytes into brown-like adipocytes leading to
activation of UCP1, OXPHOS and fatty acid oxidation (Tiraby and Langin 2003). Indeed, the
adipocytes  of  SSAT  mice  were  transformed  from  fat-storing  white  adipocytes  towards  fat-
burning brown adipocytes as mitochondria number, palmitate oxidation and expression of
genes involved in OXPHOS were elevated in the adipocytes. No induction of UCP1 was
observed  in  WAT  of  SSAT  mice  whereas  UCP3  was  elevated.  However,  it  has  been
suggested that UCP3 does not participate in the regulation of thermogenesis in the same way
as UCP1 but it promotes fatty acid oxidation (MacLellan et al., 2005). In line with our results
that the adipocytes of SSAT mice were converted to fat-burning cells, Jell and coworkers
have demonstrated that the content of malonyl-CoA levels were significantly decreased in
WAT of SSAT mice leading to increased fatty acid oxidation and reduced fatty acid synthesis
(Jell et al., 2007) as occurs in mice lacking ACC2 (Oh et al., 2005). In disagreement with the
results of Jell and coworkers, it was noticed that expression of fatty acid synthase was
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elevated in WAT of SSAT mice but this may be a compensatory increase in response to the
reduced activity of fatty acid synthase. Based on gene expression studies, it seemed that FFA
uptake was enhanced in the adipocytes of SSAT mice because all of the studied FFA
transporters were upregulated. Furthermore, release of FFAs through lipolysis seemed to be
diminished in WAT of SSAT mice because circulating glycerol levels were significantly
reduced in SSAT mice during fasting and serum FFA levels were unaltered. Moreover,
AMPK,  the  inhibitor  of  HSL,  was  upregulated  in  WAT  of  SSAT  mice.  The  expression  of
HSL was enhanced in WAT of SSAT mice but again this may represent compensating for the
decreased activity of HSL. Taken together, circulating FFAs seems to be channelled into
WAT of SSAT mice for combustion, leading to severely reduced WAT mass.
Although activated polyamine catabolism resulted in reduction in WAT depots, this led
to the development of organomegaly and an increase in lean body mass, especially in female
SSAT mice. An increase in tissue size is typically caused by accumulation of substances e.g.
fat, glycogen and iron, hypertrophy or hyperplasia of the cells or congestion from heart
failure. In SSAT mice, the TG contents of internal organs and skeletal muscle were
significantly reduced and glycogen accumulation was only evident in the heart (unpublished
data) thereby excluding the possibility that the accumulation of these substances could
account for the organomegaly in SSAT mice. Histological examination demonstrated that the
cell size of internal organs was unaltered and there was no sign of malignant transformation,
suggesting that benign hyperplasia contributes to the development of the organomegaly.
Since polyamine depletion caused by activated polyamine catabolism has been shown to
reduce cell growth (Casero and Pegg 1993; Hughes et al., 2003), other factors than
polyamines are enhancing the proliferation of cells in the internal organs of SSAT mice. The
underlying mechanisms need to be investigated in future studies.
Activated polyamine catabolism slightly affected the body weights of SSAT mice
because they were smaller after birth until the age of 2 months but otherwise body weights
remained unchanged or were slightly higher. The reduction in body weights in young SSAT
mice  is  explained  by  the  loss  of  WAT mass  which  was  observed  already  after  weaning.  In
adult mice, the development of organomegaly and the heavier skin most likely even up the
body weights of SSAT mice. In disagreement with our results, Jell and coworkers reported
that body weights of SSAT mice were lowered at the age of 30 weeks (Jell et al., 2007). One
reason to account for these inconsistencies may be the fact that Jell and coworkers had their
SSAT mice in a C57Bl/6 mouse strain. However, in agreement with our unpublished results,
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Jell and coworkers demonstrated that SSAT mice are protected from gaining weight if fed a
high-fat diet (Jell et al., 2007).
Activated polyamine catabolism and energy metabolism (Study I). The involvement
of polyamines in the regulation of energy metabolism has previously been poorly understood.
Our studies showed that activated polyamine catabolism enhances energy expenditure since
oxygen consumption was increased in SSAT mice. In line with the enhanced energy
expenditure, SSAT mice exhibited increased food intake. This may be at least partially
related to low leptin levels which stimulate food intake in hypothalamus. Hairlessness per se
did not seem to increase energy expenditure in SSAT mice because oxygen consumption was
increased before and after hair loss in SSAT mice. Organomegaly may increase energy
expenditure in SSAT mice because larger tissues consume more oxygen through metabolism
but enhanced energy expenditure was also evident in young SSAT mice when they did not
display organomegaly. In addition, an increase in locomotor activity accelerates energy
expenditure but this present and previous studies (Kaasinen et al., 2004) have demonstrated
that SSAT mice are hypoactive. The reduction in WAT mass may per se increase energy
expenditure because the loss of a metabolically rather inactive organ elevates oxygen
consumption. However, the enhanced rate of WAT mitochondrial oxidative capacity and
fatty acid oxidation most likely contributed to enhanced energy expenditure in SSAT mice as
has been observed in another mouse model overexpressing PGC-1 in WAT (Tsukiyama-
Kohara et al., 2001). However, one unanswered question is whether enhanced fatty acid
oxidation only in WAT was sufficient to increase the oxygen consumption and lower the RQ
values so markedly in SSAT mice. Ketogenesis, which occurs mainly during high rates of
fatty acid oxidation when large amounts of acetyl-CoA are generated, may reduce RQ values
but it is likely that ketogenesis was reduced, not elevated, in the livers of SSAT mice as
serum 3-hydroxybutyrate levels were decreased in SSAT mice in the fasting state. To clarify
the impact of WAT on whole-body energy metabolism in SSAT mice, fatty acid metabolism
needs to be investigated in more detail in skeletal muscle and liver. Furthermore, mice having
WAT-specific overexpression of SSAT could also provide valuable information.
Activated polyamine catabolism and glucose metabolism (Study I). The impact of
polyamines  on  the  control  of  glucose  homeostasis  has  remained  largely  unexplored.  It  was
observed that SSAT mice exhibited increased insulin sensitivity as demonstrated by their
increased insulin-stimulated peripheral glucose uptake in insulin tolerance test, improved
glucose tolerance and lowered fasting insulin levels. These results are consistent with the
leaner  phenotype  and  reduced  tissue  TG  content  which  are  known  to  correlate  with  higher
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insulin sensitivity (Krssak et al., 1999; Heilbronn et al., 2004). Corresponding with the
enhanced peripheral glucose uptake, the protein amount of plasma membrane GLUT4 was
greater in WAT and skeletal muscle in SSAT mice than in wild-type mice (unpublished data).
In  WAT,  this  was  most  likely  related  to  the  overexpression  of  AMPK  and  PGC-1.  In
addition, the enhanced glucose oxidation in WAT demonstrated by Jell and coworkers (Jell et
al., 2007) was apparently attributable to the AMPK-induced increase in glucose utilization
since expressions of HKII and PDH E1 component -subunit were elevated. Given the fact
that AMPK and PGC-1 induce muscle glucose transport in response to exercise (McGee and
Hargreaves 2006), it would be worthwhile to investigate whether increased plasma membrane
GLUT4 content in skeletal muscle was also mediated by these two factors. Consistent with
the increased insulin action in SSAT mice, gluconeogenesis was impaired in the livers of
SSAT mice since they had significantly reduced fasting glucose levels. Interestingly, SSAT
mice had elevated hepatic expression of PGC-1 which stimulates gluconeogenesis through
the transcription factor forkhead box O1. The ability of PGC-1 to induce gluconeogenesis is
largely regulated through deacetylation by SIRT1. Since hepatic SIRT1 was significantly
reduced in the fasting state, acetylation of PGC-1 was most likely increased, leading to a
lowered capability to induce gluconeogenesis. However, mechanisms leading to impaired
gluconeogenesis and increased insulin sensitivity in WAT, skeletal muscle and liver need to
be investigated in more detail. Our observations in SSAT mice indicate that enhanced energy
expenditure is associated with increased insulin sensitivity which has also been observed e.g.
in resvaratrol–treated mice (Baur et al., 2006; Lagouge et al., 2006). Moreover, our findings
support the results of a recent report that the levels of circulating bile acid correlate with
insulin sensitivity (Shaham et al., 2008) i.e. SSAT mice had both elevated serum total bile
acids and increased insulin sensitivity.
Polyamines have been suggested to stabilize insulin mRNA (Welsh 1990) and to be
necessary for proinsulin biosynthesis in pancreatic -cells (Sjöholm 1993). However,
polyamine depletion increases the insulin content and sensitivity to some secretory stimuli,
but not to glucose, in DFMO-treated rat insulinoma cells (Sjöholm et al., 1993). In SSAT
mice, it would be important to determine the islet polyamine content, and insulin biosynthesis
and secretion because the levels of higher polyamines are significantly decreased in pancreas
(Pietilä et al., 1997). In our study, circulating insulin levels were significantly reduced in
SSAT mice but this was likely to be attributable to increased insulin sensitivity rather than
impaired insulin secretion. However, since spermine is important for the function of inward
rectifying potassium channels (Williams 1997; Phillips and Nichols 2003), it would be
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interesting to determine the effect of activated polyamine catabolism on glucose-stimulated
activation of potassium calcium channels in pancreatic -cells.
Activated polyamine catabolism and cholesterol metabolism (Study II). It was
observed that plasma total cholesterol levels were significantly lowered in SSAT mice in the
fed and fasting states. Lowering of circulating cholesterol levels in the body can be achieved
via reducing cholesterol synthesis, impairing intestinal cholesterol and bile acid absorption or
enhancing bile acid synthesis. SSAT mice displayed enhanced bile acid synthesis and
reduced cholesterol absorption while cholesterol synthesis was increased and intestinal bile
acid absorption was not altered. Based on these findings, it is likely that the primary cause of
the reduced cholesterol levels was CYP7A1-mediated enhanced conversion of cholesterol
into bile acids. If increased cholesterol synthesis was the primary cause in SSAT mice, this
would cause induced bile acid synthesis by elevating the hepatic cholesterol pool which
augments CYP7A1 transcription via LXR (Russell 1999). Given that the mRNA and protein
levels of LXR and hepatic cholesterol pool were unchanged in SSAT mice, increased
cholesterol synthesis cannot be the primary cause for the alterations in cholesterol
homeostasis in SSAT mice. Impaired cholesterol absorption is not likely the primary
mechanism to account for the low cholesterol levels in SSAT mice as reduced cholesterol
absorption would lead to the induction of hepatic de novo cholesterol synthesis and as
discussed above, cholesterol synthesis was not influencing bile acid synthesis. The increased
cholesterol synthesis observed in SSAT mice was most probably a mechanism to compensate
for the increased bile acid synthesis in order to keep hepatic cholesterol pool size unchanged.
Increased hepatic de novo cholesterol synthesis subsequently most likely reduced intestinal
cholesterol absorption in SSAT mice due to reciprocal regulation of these pathways. Another
possibility is that a CYP7A1-mediated expansion of the hepatic bile acid pool reduced
cholesterol absorption by decreasing the expression of jejunal NPC1L1, as was previously
demonstrated by Ratliff and coworkers (Ratliff et al., 2006). The conclusions presented above
are supported by the observations in CYP7A1 overexpressing rodent models which also
display lowered total plasma cholesterol values, compensatorily increased cholesterol
synthesis and reduced cholesterol absorption (Spady et al., 1995, 1998; Miyake et al., 2001;
Ratliff et al., 2006).
The reduction in total cholesterol levels observed in SSAT mice was due to declines in
the LDL/VLDL/IDL and HDL fractions. Since hepatic cholesterol clearance was not
enhanced  in  SSAT  mice  as  evident  from  the  results  of  the  gene  expression  studies,  the
mechanism responsible for the reduction in both LDL/VLDL/IDL and HDL fractions was
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apparently enhanced channelling of newly synthesized cholesterol to bile acid synthesis,
leading to decreased formation of lipoproteins. At least, VLDL formation was likely reduced
in SSAT mice since the ACAT2 expression was decreased in the fed state most likely
impairing the formation of CEs and the assembly of VLDL particles. The second finding in
support of the lowered VLDL formation was that fasting plasma TG levels were significantly
reduced in SSAT mice. A measurement of the lipoprotein formation rate needs to be
performed to verify these concepts.
Since most bile acids are cytotoxic, there are a variety of hepatoprotective mechanisms
intended to prevent the accumulation of abnormally high levels of bile acids. Irrespective of
the enhanced bile acid formation in the livers of SSAT mice, no liver damage was observed
based on plasma alkaline phosphatase and alanine aminotransferase levels. Therefore, SSAT
mice have most likely developed mechanisms to minimize hepatic bile acid accumulation.
One preventive mechanism was reduced uptake of hepatic bile acids as the expressions of
hepatic bile acid transporters NTCP and OATP1 were decreased. Another mechanism was
increased biliary bile acid excretion demonstrated by higher bile acid content in feces.
However, the latter mechanism together with unaltered intestinal bile acid absorption
probably caused prolonged exposure of the intestine to elevated bile acid concentrations in
SSAT mice. This provides a novel mechanism to explain why SSAT overexpression could
enhance tumorigenesis in mice susceptible to intestinal cancer, APCMIN/+ mice (Debruyne et
al., 2001; Tucker et al., 2005).
The enhanced CYP7A1-mediated bile acid synthesis in SSAT mice was attributable to
increased expression of PGC-1 in the livers of SSAT mice. PGC-1 has been demonstrated
to be a critical activator of CYP7A1 in mice and humans (Shin et al., 2003). Nonetheless, the
consequence of stable hepatic overexpression of PGC-1 on cholesterol homeostasis has not
yet been demonstrated in vivo. However, transient adenoviral hepatic overexpression of PGC-
 has been shown to elevate total cholesterol levels by increasing VLDL production (Lin et
al., 2005). Thus, this present study is the first to demonstrate that the activation of CYP7A1
through PGC-1 is an efficient way to reduce plasma total cholesterol levels in vivo.
Molecular mechanisms leading to the activation of peroxisome proliferator
activated receptor  co-activator 1 in  white  adipose  tissue  and liver  (Study I-II). The
metabolic phenotype of SSAT mice was attributable to the increased expression of PGC-1
both in WAT and liver. When we investigated the activator of PGC-1 in WAT, it was
confirmed that the known and presumed consequences of activated polyamine catabolism
such as hairlessness, putrescine accumulation, oxidative stress and elevated cytokines do not
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have any influence on PGC-1 expression in SSAT mice. Our mRNA and protein analyses of
WAT samples demonstrated that the effect of activated polyamine catabolism on PGC-1
was most likely mediated by AMPK (Fig. 15) which induces PGC-1 in response to exercise
in skeletal muscle. This interaction of AMPK and PGC-1 in WAT has now been observed
also in recent studies (Crowe et al., 2008; Sutherland et al., 2008; Gaidhu et al., 2009). In the
liver, instead of AMPK, Akt was most likely the key modulator of PGC-1 protein stability
and activity (Fig. 15).
It is postulated that SSAT overexpression accelerates the overall flux of polyamines in
the polyamine cycle and the continuous supply of putrescine and dcAdoMet produced by
ODC and AdoMetDC keeps the cycle running. The consequences of accelerated polyamine
flux are ATP and acetyl-CoA depletion. Low ATP levels then induce the cellular energy
sensor AMPK (Fig. 15) which inhibits the formation of malonyl-CoA. Furthermore,
enhanced consumption of acetyl-CoA reduces the availability of acetyl-CoA for malonyl-
CoA synthesis. This polyamine flux theory was tested in SSAT and wild-type mice by
blocking the putrescine formation through ODC by administering DFMO. The DFMO
treatment clearly reduced the rate of polyamine flux which led to a subsequent increase in
ATP concentrations in the adipocytes of SSAT mice and to the reversal of the metabolic
phenotype of SSAT mice. This confirmed our hypothesis that the polyamine cycle can be
considered as a futile cycle and the shortage of ATP in WAT was the key contributing factor
leading to the metabolic phenotype of SSAT mice.
Interestingly, accelerated polyamine catabolism did not activate AMPK in the liver
although a slight reduction in ATP concentrations was observed (unpublished data). In
contrast, polyamine catabolism caused a reduction in the phosphorylation of Akt in the livers
of SSAT mice and also in human hepatoma HepG2 cells which has been previously noticed
in glioblastoma (Jiang et al., 2007) and breast cancer cells (Nair et al., 2007). The interaction
of activated polyamine catabolism with Akt in the liver cells is poorly understood but
activated polyamine catabolism did not have any effect on the protein levels of total Akt and
the upstream regulator of Akt, PI3K in SSAT mice. Further studies will be needed to
investigate the mechanism leading to the reduction of Akt phosphorylation. Therefore, the
mechanism causing the activation of PGC-1 in the liver seems to be different from that
observed  in  WAT of  SSAT mice.  It  is  tempting  to  speculate  that  because  SSAT activity  is
lower in the livers (4-fold) of SSAT mice as compared with that in WAT (22-fold), the
depletion of ATP pool, as a consequence of activated polyamine catabolism, does not reach
the threshold needed to activate AMPK in the livers of SSAT mice. Another possible
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explanation is that the mechanism to account for why activated polyamine catabolism can
induce PGC-1 is tissue-specific. This is not unexpected  because the function of AMPK
differs in liver and in WAT. AMPK induces fatty acid oxidation and inhibits the production
of cholesterol, TG and glucose in the liver whereas in WAT, the main purpose of AMPK is to
stimulate basal glucose transport and to inhibit lipolysis (Winder and Hardie 1999).
Therefore, the induction of AMPK by activated polyamine catabolism in the liver could
disrupt normal homeostasis. Instead, Akt is involved in controlling vital cellular functions
such as apoptosis,  cell  cycle progression and glucose metabolism in several  tissues (Franke
2008). Whether Akt is also involved in the signal transduction between activated polyamine
catabolism and PGC-1 in WAT will require further investigation.
Deficiency of polyamine catabolism and glucose, energy and lipid metabolism
(Study III). To study the effect of SSAT deficiency on glucose, energy and lipid metabolism,
the metabolic phenotype of SSAT-KO mice was investigated. Under basal conditions, SSAT-
KO mice had SSAT activity comparable to that of wild-type mice and exhibited traces of N1-
acetylspermidine which most likely reflects the presence of other acetylases than SSAT. The
deficiency of polyamine catabolism did not have as dramatic effects on tissue polyamine
homeostasis in mice as the activation of polyamine catabolism. In SSAT-KO mice, only
slightly increased spermidine pools appeared in several tissues including WAT similar to
those observed in vitro in SSAT-deficient embryonic stem cells (Niiranen et al., 2002). SSAT
has been proven to be the key enzyme in the backconversion of spermidine to putrescine
(Niiranen et al., 2002) whereas the catabolism of spermine is mainly achieved by the action
of SMO (Vujcic et al., 2002). Thus, this slight increase in spermidine levels in SSAT-KO
mice was best explained by the lowered rate of polyamine cycle due to the absence of SSAT
with the concomitant compensatory increase in the conversion of spermine to spermidine by
SMO.
Since SSAT-KO deficient embryonic stem cells are more resistant to the effect of
DENSPM (Niiranen et al., 2002), it was a surprise that SSAT-KO mice were more sensitive
to DENSPM-induced toxicity. The cytotoxic effect of DENSPM has been considered to be
related to its ability to induce SSAT, depleting spermidine and spermine pools, increasing
cellular oxidative stress through the generation of H2O2 and inhibiting mammalian target of
rapamycin-mediated protein synthesis (Snyder et al., 1994; Casero et al., 2005; Jiang et al.,
2007). As expected, DENSPM treatment had only a negligible effect on tissue polyamine
content in SSAT-KO mice and the tissue accumulation of this SSAT inducer did not differ
between the mouse lines. Therefore, the mechanism leading to cytotoxicity of DENSPM in
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SSAT-KO mice is not attributable to the size of tissue polyamine pool. One possible
explanation is that as SSAT is not only the target of DENSPM, the binding of DENSPM to
SSAT may protect from harmful effects caused by other targets (Pegg 2008).
SSAT-KO mice did not have increased WAT mass when compared to their body-
weight matched wild-type mice. However, Jell and coworkers observed that a ~20% portion
of mice showed higher WAT mass than wild-type mice even if body weights were not
elevated in SSAT-KO mice (Jell et al., 2007). Furthermore, they demonstrated that a SSAT
deficiency led to increased susceptibility to high-fat diet-induced obesity which is in
disagreement with our unpublished data. The reason for these differences between the studies
is unknown but Jell and coworkers did not use littermates as controls and they may have had
their mice in a different C57Bl/6 mouse strain which could account for these discrepancies
between results. Taking into account the fact that WAT mass was not changed and there was
no significant difference in food consumption between SSAT-KO and wild-type mice, the
conclusion is that most likely energy expenditure is not altered in SSAT-KO mice. Indeed,
SSAT-KO mice have been reported to have unaltered energy expenditure (Jell et al., 2007).
Our study showed that glucose homeostasis was altered in aged SSAT-KO mice because they
had increased fasting glucose levels. Insulin resistance with a concomitant reduction in
peripheral glucose uptake was also evident as seen from the results of the insulin tolerance
test (Fig. 15). Moreover, Jell and coworkers demonstrated that glucose oxidation was
impaired in WAT of SSAT-KO mice (Jell et al., 2007). However, glucose tolerance was not
impaired in SSAT-KO mice because insulin resistance was compensated by higher insulin
secretion from the pancreas. Interestingly, histological examination of aged SSAT-KO mice
revealed renal alterations resembling the characteristics of diabetic nephropathy (Fig. 15).
SSAT-KO mice were insulin resistant and therefore, one could expect that these mice
show hypertriglyceridemia and hypercholesterolaemia as insulin resistance causes e.g.
enhanced production of TG-rich VLDL and cholesterol-rich LDL particles (Taskinen 2003).
In  contrast  to  our  expectations,  no  changes  in  plasma  TG  levels  and  total  cholesterol  were
observed in SSAT-KO mice. As SSAT-KO mice were hyperinsulinemic, this may
compensate for the hepatic insulin resistance and thus maintain lipoprotein production within
the normal range.
Jell and coworkers have suggested that the obese phenotype of SSAT-KO mice is
attributable to increased acetyl- and malonyl-CoA levels which enhance fatty acid synthesis
and downregulate fatty acid oxidation (Jell et al., 2007). In addition, the deficiency of SSAT
may decrease ATP consumption causing the subsequent reduction in the AMP/ATP ratio that
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will reduce the activity of AMPK and possibly also PGC-1. The mechanism responsible for
insulin resistance will have to be investigated in SSAT-KO mice in future studies.
PGC-1
pAkt pAMPK
Bile acid synthesis Glucose transport
Mitochondrial biogenesis
OXPHOS
Fatty acid oxidation
SSAT
- +
Overexpression Deficiency
Diabetic nephropathy
Insulin resistance
Figure 15. The main findings in SSAT and SSAT-KO mice.
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7 CONCLUDING REMARKS
Our results summarized in Figure 16 provide new evidence that activated polyamine
catabolism, but not the polyamines themselves, can enhance energy expenditure, increase
insulin sensitivity, reduce circulating total cholesterol levels and cause organomegaly.
Furthermore, we observed that the deficiency of polyamine catabolism results in insulin
resistance.
SSAT
Hair loss
KFSD
Liver regeneration
Pancreatitis
Fat mass
Carcinogenesis
Cholesterol
Energy expenditure
Insulin sensitivity
Organ size
Depletion of higher polyamines
Elevated putrescine content
Reactive oxygen species
Reduced acetyl-CoA and ATP
Reduced Akt
Unknown
Figure 16. Physiological consequences of SSAT overexpression. KFSD, keratosis follicularis
spinulosa decalvans. The shading of the boxes presents the most likely cause for the
physiological change.
Our studies revealed for the very first time that the polyamine cycle can be considered
as a futile cycle and the acceleration of the rate of polyamine cycle due to SSAT
overexpression causes depletion of the cellular ATP pool. The high AMP/ATP-ratio results
then in the activation of AMPK with the concomitant induction of PGC-1 which improves
glucose and energy metabolism. Moreover, the activation of AMPK suppresses ACC, the
enzyme converting acetyl-CoA to malonyl-CoA explaining why the formation of malonyl-
CoA from acetyl-CoA is impaired in WAT of SSAT, the previously suggested reason for the
lean  phenotype  of  SSAT  mice  (Jell  et  al.,  2007).  Therefore,  our  findings  deepened  the
understanding of the mechanisms underlying the altered body WAT mass in SSAT mice.
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Our results provide evidence that the ideal concept for drug development for obesity
and type 2 diabetes is the enhancement of ATP consumption and basal metabolic rate since
these are associated with weight loss and beneficial changes in glucose homeostasis.
Currently, promising anti-hyperglycemic agents are SIRT1 activators which enhance energy
expenditure, increase insulin sensitivity and protect against high-fat diet-induced obesity
(Lagouge et al., 2006; Milne et al., 2007).
Another novel finding in our studies was that polyamine catabolism is a potential new
target to augment CYP7A1 expression and bile acid synthesis in the liver. In other words,
activated polyamine catabolism increased the stability and activity of PGC-1, the critical
activator of CYP7A1, by reducing activity of Akt. Thus, our studies provide support for
previous observations that the activation of CYP7A1 and bile acid synthesis is an effective
way of lowering circulating total cholesterol levels at least in mice.
Our findings open several possibilities for future studies. For example, it would be
important to elucidate the cause for organomegaly and especially for cardiac enlargement in
SSAT mice. Second, the molecular mechanisms by which activated and deficiency of
polyamine catabolism affect insulin sensitivity and gluconeogenesis on chow and high-fat
diet need to be clarified. Furthermore, the detailed mechanisms to explain why activated
polyamine catabolism causes low cholesterol levels and the phosphorylation of Akt should
also be investigated.
In future studies, to overcome the undesired effect of SSAT overexpression in nontarget
tissues, mice having WAT- and liver-specific overexpression of SSAT would be feasible
study models. Although the regulation of energy and glucose metabolism is similar in mice
and humans, and CYP7A1 is also induced by PGC-1 in humans, it should be investigated
whether these results can be duplicated in humans. If the future studies support the role of
polyamine catabolism as a potential drug target, the development of WAT- and liver-specific
SSAT activators would be of interest.
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8 SUMMARY
The main aim of this study was to investigate the effects of activated and inactivated
polyamine catabolism on glucose, energy and lipid metabolism in mice. The following results
were obtained:
I  SSAT mice had reduced fat mass, low tissue TG content, increased mitochondria
number, enhanced basal metabolic rate, high insulin sensitivity and OXPHOS accompanied
by increased levels of AMPK and PGC-1. Activated polyamine catabolism caused depletion
of the ATP pool in WAT of SSAT mice resulting in the induction of AMPK which in turn
activated PGC-1.
II Activated polyamine catabolism reduced significantly plasma total cholesterol levels in
mice by enhancing CYP7A1-mediated conversion of cholesterol to bile acids. The activation
of CYP7A1 was attributable to an increased stability and activity of PGC-1 which was most
likely elicited by activated polyamine catabolism–induced reduction in the activity of Akt.
III SSAT-KO mice maintained normal polyamine homeostasis but showed abnormal
glucose homeostasis during aging. Increased fasting glucose levels and insulin resistance
were observed in aged SSAT-KO mice.
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